var title_f15_13_15568="Junctional EB Herlitz 1";
var content_f15_13_15568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 502px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH2AU0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDnTHkZHakKEjirroAOKibCdK8k+qKMkXHSs+5i8t1kHY1uOpZSTis67jCqDnIzQTJXMzUIxLEWHUc1hMfLlHv1roZwAZF7EcVz10v74EdCK0ic8kUHBEjn0NV5huYlea0niPlMSPm6/hWanMzEdOtaxMJjIFxcgAcVpXVpkocVUshvnyB34rpGiyEPXiplI0oorW1qY3jkPAIHFabk7cds5pp2iJQfSo3lwDz0qDvg9AtoIbidkmcKeorQNk0AGxvl7VzkS+fI8gYqwPBFXbbVbi2YJc/Mo6E0yLu9zdTcF+aq13GrDJFMS/8APIxikupNq8c5HNI1krxH2tuscw/ukZzWPr4AvE8v7wX1961Irr/RsOOgwD61hEm61Q9eOKa3POxelOxuaBaGSYMufc12Xmi2AjjXMmKy9OjWwt12kb2HHFaFsoBMkx+Y9qiTPNLdnBubzJPmc9TWouEj5HSsafUliwsa5+lVLzVpI0LMpHFZso2Li7CA4rOlvsgtu4rn5dTkuMbAeTTWSdsg5AxnrRcZLfXxmm2ITzV7T/lTGMnvWFBGfN59etb1v8qgDvUyAsOdxAzio0jCyEmpFAY471aEY29MmhMCK3nCyfKK3BLvjz7ViSwFTuUc1csnbbg9qLgy7KpNuPWs4rskz2rbj2yW4wPaqVzEGB4qiBkZBUUMRzVMXHkuFc4WpGuoSRtYc0xFmJiKuwnctZySqehFWYJNp5NNgWitNPHSnq6svBFRtTjoIvwziWLa3B6HNZqRvY3EhKiSJucinRuFk2t901Mdy8qcr6V20MSo6MwnTvqUblmnnRoIShB69K2VLlRk9qbbyxsuOpqYqf4RxWk6nOtBKDRwrDawyCKcyqVyafKQ2MVGy8jmvLPqytI+MiqNyp8o85zV+VSDnFVJx8oFA+Ux7hjkk/3ayJkJ8g49c/nWzcrjg8VlXGfIBBzh/wBK0iznnEr3H3Xbs3GKx0GLgr0yprZuebQ+uax7hds4I7jFaJo56kdi3pKgDcenaty3nWQ4U529azrCDbEhx1FXdLtDDNI5OQ1JmkI6FqZGEQYjiqE0gMbYNbVwgZCB0xXI3zPFPt6KT1NFiud7F3TgRyMnJrUk057yItuA9qraRLEQvK1ryyQAbklCuo6A0mdEWrGAols5MN90nHPBrQGZkBPQ+9VvEEvmywXCMCNu1wP51PDtaFWSQmNh6VDeo4VOZ8pBPMyh1xwBxUfhxVkuJJpOxp+oJi3J74OaboVs0qIQ+EAycd60Wx5uNlrY7S2Xe3mluOwrTjtzKd3b1PSqloiQxqY0Z8DqelaIyVDSuQv90cVlJnEQTG3t1ztDN7CsSQtfSSNL91egFaF8SIi/AQevWqumcxMcfeNQxlSONRECuBtNXGI+bn+Gm+Scyg/WmhGk2sPTFSUZatifB9a1kuNkYFZ9zauGJpV3eXjB4qgNm3lDjIrSgYZzxXLwzsnBz+VXoL4AdalgdKUUx8d6qykwnINVU1KNYhkjIrOvdVVyVB49qEDNe01baHjJ5BzQ+pM4IArk4LpnvTtyBjBNasZOQc/WtLGb03Jb6Qypz1rKaVscE5FaxX5fm9Kx5cLIw71RO5bt7mQDAY59atreS4A35rNtWbndipmz1HWmM1IbyUD7xq3HqDgfNWDDNzyavREMuaQjWe8JXjrU0N4xXnn2rGIOck4q1Aw24oCxrLOT8yHawq3DqZCYccisQNjpTzIGxv5NawqEOJUZAO9MK4Oc1ZaMY61CRtB3Vzn0qK8nLCqs6gmrcrcHiqUp5oLMy+iyDWZcxbbNcc5atq8/1ZzWbcDEcS+/NCMpGdcR4tG3cZHH51mtFukUEdAPzrevY/3KgmqEaBpiSOnStEZzjct2sWIwMdOlaMcW1RxVWF8VoxENGCBSuC00K8zADFZ+o6el3bNwA2Kv3gwCadGu6An2qkwcTj4bE2ezbKWkPTngVu6daiQEyYYn1rNSJ5b2TGcZ49q67S9PKoC1ORpRjbcpT6PHLF8vBA7VDa2P2eI5JA9DW+6BJMZ6dap38yYKLjpxio5bi5lGRz2oNuhcA8EYrX8KW+LdMJxt5zWPesqhQepOMV2Hh5NkCqq5BXrVS0VjzcW+aRuwKI40UKcN3qSWJY2YzMCMcULIEjAchsdPasHXdS2qecCsmc6KOu3/AJkqwIep7dqvaZHtgAPSuSsmN1eNM2c54FdnYDFuxI6Cpn0GNjCmaTB7U1QVhU+9JHwrO2fmqVlPlRj35FICB/mPIpyov90Yp0q5O70pyKeMiqJI1hUtggU5oIl/gzU6r81K65pAinPDHs4UVnssQcjABHer8qswbBxiuW1yWZPlgVvL7sKcTWNPndjSABnVlxjvg1pRTFRwoP41zmkhvs+9iSa2YG+XOa0PQWAgldmh50jDnaBUBhR3ywyaTcGGAeajmnEUZyee1NA8PCPQsPHFEuQOaVVEynAwagtYpZzufIHpWzBbbUwFqjCVGLMd7V1yV5qzbEgYatFoRt5FZtwdsmIuT7UrGMsOWSDjnpToDtcc1WidyMSIR71KDgg0jmlTlE0gOOaYTzxTwcxg1H3NSZj2PFVp5ivbipyT6VBNGJO9SfTwSKrShqide9Djy2NM83IOak0cL7EF0B0NUJo8lSegNaMnz81TYbuDTRlKNmVLpdwA96rxxAAnvV10GcntUTYVwBVmUiFOpFadtxGAetU0UGQ4FXkAwdtBJBdDOadagmIrinMpar1pGrp0ximN6oztNtY0uX3qM5reeUImEA6VnXMRRiyjBpFkZlIOeKEyr2Ql258ppD1rFTLbpGxk9vStueLzIAufrWRqai1i/CqMHLVtmUxEupxx9QOa9C0xRHbLxjiuA0BRLfGZh14+ldjcajFbw4LjgYxUs86o+aRY1G88pTzxXOXUZ1GFtzFfQ1Xa/e9uW35VFPA9av2hXeAo6Um7Eoi0SyZJAhGNvU11VxF5VsAjck1Qs2Ec+4AEGtXidvM2/Kg4rNu4pFVYzhE696ZJLulIA4XpVt08q3aU/efgCq9tAdu49SeaZI1ULv0q0IsEZpYV+c88VNwBk9qTAjEeOaYzBW5HFPmkLL8o6VUZiTSAzPEVwYQsUR2l+SfQVjQO8/7tTlTwSe9XvE8DSxwPzwcN9Kj010tirKgZR0B5qj2sDTi43YksKQqI4xjHX3pVlEacmlv7kzyM7gAk9AMAVh6hdSFdsKk+prSKO2paETQTUdruxI2jir2lW7XjefNnb1VfSuW0q1a+uVRpD5aHLD3r0XTotqBQMKOBVWscDqc/Qt28O3AUDb6VbLBF9KaBtTPYVlajdMcRJ940xco24uWlnaOM/KO9WLeBeBg5PU1DZWxwABk9zWxBAcgnpQRJIjMShR8uarPCoJ+Xitd4gFz6Vn3BVM80yeVS6FDzXhJxyvpViJkmXctZ91I0zlYBuP6VAlrdxZII+bnGelKxy1cPd6G6w4qBwewq4yAComUZrM9eLM+aPIOaznXaxHatm4AANUWQOSMc1izppyKRznHrTOASD1FWJlKnIHSmGPIDevWmgmk9SpJznAqEQ4YHrVqQAA+tR9lqzlkRouHNWIvSmBevrSqwUZNMzFkO0ACpNHvEeWRARuHeqF7LiIkVj6Fcm1v3aYZVzw3pTZUTuXTJ65zVcQkSknpU1nOj528gjg0s2OTms7lSiQPKI1PGa5TxVdYVVP8AF0rbvrlYo2OenOa4bV53upPMPTPAreKuctdcqLWl3MkCZTrU8stzPdK78x9TRpMYLEkZAFF5dCF8eRJj1HSr5TzJOxYe4hglDPjB6VuWfzRKyjGa4qOKbUbxRCMYPG6u60q3ljQRyDlRzioqx0CD5maNomcZNbVqdoEZHynqazraMggYrZiVI4Ru5JrNR0KkRXKiaQY+6OgqK5UJH8lXiqhQAMGq8yhuKjYgzIbjYSCean83cMk1Vu7cqxZaqCVwec8UFGsjA8Z61I0IIyBmqVvJnBJrVhGUBpAZl1AChVgGX0Nc3qNt9nBaElR6V2M0eWxisPxAEtLCSaRcgDAHqT0qomlOpUi7RZy9slxdSFWf5c4xV68sxapyQDjnNGg5ISViATzj0qfWm85lGcljitT3INqC5hnh22HzTMvLmuwtkA4xWLpkaoqgfdAFbgcoo44I60rmTp3eg29uAiemKybFGmkaVxyTgD2pdTlMkyxDv1q5YxDChaZMlZWNOyjXPSr3EfJFNsowI8mqupXYiRsYxTMbXdgv75I0bJHArnVmkv3JUlIifzquZX1CcryIFPJ9a3bG2AReAAKZduVEllaBUAQbR71dNqhAzyaesZVR6Up+tBjIrSDnJqJ0z0pybnJBBpHBQ81idqsitJFk4PeoRBtbJq2WJYYHFNkORUstSsZ8sYZjiofLYcHpV51IbikYBhjvTFzswrlSshB9Kj7itC8j2KSRzWY+S3oaZnKQ9ziNT603OVGaTBbAHIFOUDJBqjEo3oyAtUpLcHjqK0zGZJMkcCkeNMcdRQXEpWt7NZjY5LKOhqxPryiPgMc8VHLEpPTIrPuLZc8DHNFirt7FSW/lv5mjQFYgefeq93AUhA7huB6itGGFImCKuBnJPrS6mgE2CQRxitF2RzTT6k2i4DHI7VueTE6/vFBHcGuWs7vZdFU5xWnLeyyOuAQKaTPPk02zSt9LWVw8GIyp4PrXR6ZbSKn7z5mNU9DeJ4xuYAiuts4Y44RI2MdqTd9BW5VczUt/KbLDk0TTAbeenapbm5EkhwMYrI1KXaAVNQxXLtxe7W6jFJHdq/IIzWEUluDwTSiOe0wSNy96lrQRvgiQ9M1XuLRXBKiqVrqCliDwa17eZHUZIrOxRjpmJyK2bObKAVWu4FJ3KahhYo3XiqtcDYh+ef5hxmsfx5bB9BDKPuSDPuOn9a09NBkYsTxVnWYEutMmt2GQVyPr1oWjKpu0ked6d+7gQdDiq+rXAiVGboDkmpbclAUYYK/KfaqWrbZSicHJxg1t0PbjK6RteF7uO6uol3/KT611eptsZkA+7XHaPZw70aD92VGeK6e9fGnBmOWBwT60ka1GnNWMuAma6d26LxXQ2Ea+WDXPaZyuf73JrqdIUPuB6Cgwql+Ro4bTpzjrXEapcNcXIgjJ68+wrd8RXpjhYKcYGKwNNiyBI3Lt1pPcKcbK5p2NmEQBD8vpW1ax7U6VHYwgxA1YnuEt4jkirIm7uw6aYIOcZqlJegHtWRf6kuSwYAdetYM2qvJITEp2jvQRynoRyFJUDNVJsvzVzcAn1qjPnPynmsTWJDjg4poUKDk09z0yOaiY0FjZGXPWq5fDU9lAzzk1G+OvegTZXvfnIrMmXnA61o3TqMEmqSrvbJ6UzNiooVRxURXMjEdCamcoo4Ymoo2Dt7UyBkakZ4pskQ+9mpm9aQ4IAoZcSm6gdazNQkWPJbpW1MoxmsC9+eUg9KImqVkUZrorjbwxPT2pl/cEIGbliKju4y15u6KgqjcyNczALnaOK2ijjrO+iH284ifzMFie1WZNXmdCkabG7E0yODC4x9KRoup9Ko41h3e7Ox8NJKdPWe5cBuvWtR9blDCNHxGO9edxaxc2+IomDR9wa2dN1FbliroEYdvWokjKWmh3Ed+JFUkjPrVTUbgYX5hWI0xXGOKY7mRwGJqLEm1FqCwgY5qx/aazrjFZSRKYsEUyz2q7DpipJJrhcuWQYNS2dzMvHNTxIjjrU8dugORipKJEuJCmTmmC4IbkVZSMeXnPymqVwpWUYpoDpNJdQnLYJ7VoS8qe9cpDdNEo5rQt9SLLh+lJgYGv2Sw3pkUEJIe3rWDqapCsL453ZNddrUyyQEZGc5Fc8yCaLayhsdc1cXoenhqnMrF3wuUuY70qMlIcj65q3dXa/wBlrFnn72fwrGtp5bTctqNgYbWx3FV7wyNCFBwuMY70opnfGXc2NHmBVSDkV09ndeVn6VwWjSeWyITx0rpz+6uRHuyAP6VQ3C5T8Q3BeUAdzVjTyoReeBWTqIee4kKnATj8avWyeXBGeQccg+tJ7lcmh0gvVgtwAR0rmNe1ZhE2Op4AzS312EjOTwK5hp2ubsiUEKDx71ZhKKgPt5TJjzmIz61qRIoX5cYpqQxtGAVFH2I/wuwHoKZB6TKVKgKay7uUo+B0qZnKk85qrP8AOawKhuJHKZOtK5xk1HCpXPFLIaCpNELnLZ71G+ehpWPzVHMSMEUzJlO4Yd+1QqwcjHanzjIPpUUZMQPAP1piIJWAuCoqxGjKB70yOHdL5pzk9qvxRgIc0DexVkTDDn8KaR8pqZuZCe3amyY2nIqSomdISA2TWNcTAMTx1rT1GYRAkn6CuXu5y7FVHzVcUVUqJKyEvZd6jYRvZuntTbWHaMkEE0kEADktksf4jV9Izt4NbbIxUOpGinv0qjqjMkaleh61rKSBgimzWizLzUKQ6lO8dDmg46nrUf2mUMSjFfcGtN7EK7DGRTDp6E5ANXzo8urQnc0tO1B2hAuCzehzWxbzc5UjB7msGKNIAFxk1YR3bhSQPSok09jSOGbWp0a3SIhMhA/Gs6XU4IJyQxINUFt2k4ck1MumNHzLtx/dPOai5pHBM1F1VJAuwsue4q9BqAKYLse3Sse2tCT0wR0xWxbaeIwC3fvSOn6oktR6XD8qkjAdeal3M5BZufWpRbgMGxTzBzxQYywyIGdwODkUkdwRwakeIiPPeqjJkn19aDGVK2xFqU5YjBqjp+pBr0xPwp6H3qeaM7STzis+W3COJEHTmqREL05XR0jLCFy2ATUIhXa7Y5I4qGCVZoI2zzVljlQKo9RO8bmOi7Js4OQc8V0dw5DrKRguAefpWHL5kcmYyM1DNcXkxCuxI6D6Vmou50+0vYt/bI45yHGRnO6p7nU4WHBO0Dis+C0J4c8n1qwNLLKTkYxVcpn7V3M6S4e9m+XIX09avRWa7MEc1NYWYiB7nNWY48yNninsZt3IIgYhhvmHr6VN5wxxipDHzjGRTGtVY55FMaOokfnNNWVScHrTHOVqDGDnNZgloWDwc5qJjk0xmz3qCMuZDnoKkLJ6j5eQcVAck8GpXbtUBbr6VRnIiyrPzz71CEG9+SanI+UkUgyCcDg96CULAACKlc5yOgNJEqqOevrTnGBkDNBZCTnOBwKqTy7Qc9KsTsApNc1ruoFMRKcu3T2ppXLTsjO1e+Msxjj6iq1tas3PIY9abFFk/Nkk85q15yWsByWDGremiM5dyyLfywMFePWnHCgnaOPSsWAy3NwWLsFBrXKsAMDIqNTanHmQzzNzYHGa0YrcMg7selMs7TcQ7CtmKLaBhaRbXKZpsV67cmoX09gdxXIFdAkBYZq3DApGCtBnZN6nITaeSA23BqJIGXgAn8K7Sax3/dxSrpyiMdN30qbm8eQ5i3tXfleDV+DTWdtzktW/BYKg/vVdihCptAGDSFKpFbGRBYd8cDtVvyMDGOlaUUOz7ozTjEWPSmYyqXM9IcoeKGg46VomIKuBTGTHWgyvcy3h+XkVQliAJ4ramQYNVZIcg8VQuUw7iPHQcVRkRcnd0rcnjAI44rPlgBY9qo5qlMyI3a1uCGPyN+layybgOapzw+YrBuarW9w1u4SU5HY1Q6VXk91mwVBFOVQMZAqJJAwBHWp0IOOaDtjIlMQJzVqMFU5HFRW5BYFugrQUAxnigGUFUAcd6SIAOxqbyQO9Ryx7DkUAKUBfd2qVEOOFzUMZOasIzY6UDsWTJ70wt+VR9+eBSMNxwDmsxLYk68ihiFJOaQsEAwKhfLGpJEkO5gM9aif5TgHNKWK5OOlM6KT1NMliSvsXPaktpC/0PQ0k6boeetTWyFIVwOaY0lYfyDzyKbLKwUgcVK7YTcxArB1jUBEpAYZPQCna4RIdW1NbZCM5Y9PrXKFpLiYzPksw5qy6vdTM8pznsegqvNMI0OMjsMVa00G3y6sm8wW6gjk1SlaW4Jc5xVZZmVvm3Nnsa07XfNCdq4x6U2ramSq+0dhlqrxgHI59DW1pb+YdrjLVRiRlizIq7h0A4zVq1OWSRRgg81k5HbQ00Ols4gCOORV0Iep7VWsW557itKNdxAqR1NxkMeTVuNN38OMUJHg9KniXFBi2EcRzzxUmwj6VKo546ipVXI5oJ5iCJDuwelWhCMdKFHz9OKtqB+VBDZWER6YoK47VbfHAHBpjLnrQSQsgwDVWc88CrnNQSITk5pgioUz9ahmUhetXGAFVJs59qZaM+4j+UVnypya2ZI9wqlPGA2D1pilExp4iAcDrWdcxo0XP8q3JU5NZt3H/ABA/UelVc5akOxnafckFon5I+6a17Yk9axbxBxNHw61csb1Z4wy8MOGFUVSqW0ZvQkHHtVyKXAYE1mxONgOeKnUHdnPWkdCkXE6ZNMcbs5pqvxg0qMCcZoNULGnNWUUYqKPg8VaRMDjmgspAuWGelSD7xoGB1NRmYbtvb1rMw5hZZBnHeonbBBzz6VHNL82B+dQDczcHNIZICXfBqwECrk0kSAY9adL93FMW4IgKbm7Ux5hHnB5P6VF5x5A4xxWTql9sJSL55PbtQtSlHoSapqy28eCQWPQetc4yS3EvmzfLnt6VJDA0svm3GWkB61dWEysVyB6U27HRCjpcovsTKxj5T1rPvbWVdrxKWjPoM1t/ZGjY+bHvI/iU9asQybYWGzOOwGM1PMcteEpO1jkJIZmZcDP05rc03EFuEP3icmrqRrI5CLHCmegB3fnUNyqCViMhU4A96cp3ViKOHaZWuJ3dyqgbfXvWhpNuzv8AP0FV7O0aZy2OldPpdl5a88lqg9KMfZLUt2cAC9PpWlDFjkilt4gqjAq4mAMEUzlqTuxiR57VMsWOtSJgdqeoDcnqKDFyIyuANo571YiXAGRTcVNwFpicgEXzA0/oPemhs9OtOAzjNMm4qDngZNIx3HAFSowUY28009eKBkTJhSarMcZqy55wehqpLkE4oAjc/NyKguCMVMOWOabMgIHvQVEqDpkVTuEwc+taqxAKc1VmjBGD1oZRlXCAAe9Zk6/ezWpdKccGqcyhhzxihGcomHcx4TpxWTDJ9ivQzf6tzyK6ScKV2msTVbcFePzrVHLNW1OjtFVhuUcEZFXEbHXtWDokzxW0YYkjGAa3IZM/eFI6Iu8bkwYZ54oBw1QuQXHOKXdk4HIoNYS0LccmGFWlfI61mo+OanWQY+9QVzDGdRjJqCV1x71Fh5fUCrMdvgAnmszOLK6bmYEdKuRRAAHFPWFFGVHNOdwq4oKGsNpqrdShU+9gim3tyqAlvlHrmuZvb2e8kMUKFYh/F60Fwj2LN3fM4MdvkuTy3pVWG3KZdyS5/GprayZYgoyPU9zT5JVhmECAs/Un0o22OqFNLViBBn5etadrCI49+3L0y1hOdzcZ74rSFupXBYZqTp5kjPwpZs9/51RnRtzBcgCr12RBln4AqpbRvcsHc5yeKRXuvcpiNsHDHmpbWxkmfnJz1rqLXSAVDsoGevtWrDp8SHIA4oMp1YQ+FGNpulhBkjitmOBUUBRzVlIgp6cVMwG3gUWOSdZyK6ZHapgPlyRQEJNTKAMZpnPIRMYp6tjqKDg8CkAGetBI4sDxT0AzjNMAp4xvzVCsSoAOnWl9fQVCX+bGafx2OaAJAR680hPHFMJ2jNOD5U5oGQyNzUbYNLMwz1qNjge9AbEMgwfaoPmLL7VK7/NTFcFqZQ5nKE5FQzHPJ4qXhsk1XcbmIPFIlFSdAVGKoyIMmtKb5UAxVTaBnPegsx7mMBjVCZVdCDzWxdKCTisydNpOBVIxnG6DSUXy2iYZIrQiDQnb1ArKs5dl3joGrbUZ561Qo6KxJuV8cVNDCjD0qDG7tg0sCuh6kimJyLElqAcKetMMMg6bTVrYWQEdaURnHOaQ1MZHCOOMUkvytgdKdvxVSaTkknioLiiRpttUby6Cg7jyewqG4u90myEZNFvbFm3y/Mx6mkaxM9klunzL9z+FTV+HTsAdPoBWrBbR4Hy1Z8sFSuMH2oZvGSRg3jpaW0jE4Kg1m6FH9qDTMBlu5rR1e3Z7Z0I4XJ+tZuiT/Z8RMMAjIzQjT3nsdLGqhNpySO3aqd/drbRkyBVPpRPfxog2ndIR90ZrIfSbjVLvzJATHt4BPegHzLcyp7y51W7SNSVQHpjqK7zQ9OKKu/kKKi0bw/HAUJRRgV1EUW1QAuKUmjNza0uIEGMA8UoUDingc4qQRDGSeKRztsh208AAUuPmwBxTtuKAEAwOlObaq8nmn7MimFQHG6gREfbpSKcHFSMmfpUb8EAUAPRsnrxUuM9KgXjpS7jnHagCXZk0mNrUocqKYZcmqJsJM5VazJ9QdGwOlXJ3AQgHPFc9eSfMAc5qTpowTWpbe9lJ3CrUF35kZA4PesG4WSVFEbbcdasWjks3PJGKEzWpTVjSeYb+vFOt2yrN1GcVmuxUYNWraULGAPTn61ZyzVloWjJwajB3EVFu3N1pQx3YFBmOugMACqpXipZCxPzUxuFyaRRRnTms25Qc1rSEE+1VpYc5NUBz04KOG9DXRWTBo178ZrLvIQEbip9NkPkKT2GKoxW5q+WTyKsQLgfMtV43+Xk81bhk6CglliBcdKuIPl6VDGTt61OhyOtIRyd/qMduhLyBce9Y73s16SEG2M9/WsCASXj+ddsGPUA9K2beZIo1OVAHSpZ206d9zXsLchRxjHc961FjIArJhvmzhcGtawuDLjeMUrmsqfKi5AhIwasqnJ4qNTxwKmQ8e9Bjdle5s0kQ45JrDudG8yQsq4cjBNdQF3HI60FST2BFBpGs4mBp2kBDlsEgda2ra3CD5QTjrxirSx4GO5qRUOegxQDqNhEhGKsoBjmkVQRxTkQdzUmT1FyAeBSbWNPwMcU8DpQSRBCDyKdtzxUpANNIxQIYMimvjIpWPOKid8A55FAkPyD0psuMVnXWorESB2qgurlzwQRSubqhJq5t9iaYW5qC2uxKvJGakL5OKZDjYkMh4xTA/PI4qCU7SGzxShwQeeaA5RzuCTxis+e28xgc8Z61b5zULE849aC6cnEhe1UMFXgjrSLEqAnGMVO/Lk+1RSNkelNIbnIp3XABohYheaS6IIUd6SJWK8iqM5FtBuXjrViMALz1qCFggGaVpfmwKDOxOyAiq044IqyhJXmoLj5UJ70DSuyky8gY5pGGQcUxbjMxVjyO1WXUBcjvSKkuUyrtAU96qaacb0PY1qTICmayofkvmX15q0ZM14Qe/WrUfBBqrEcNzVpenFBJdiY4FWUyBxVGNsCrEcwA61IjzQWTFdq5BHpUsencAMGNbWnRjuM1rRwIwHAqWeopKJi2NgxOMYFdBZWwiUDvUsUagY4qYLRYzlUctCWNRUwUYqNDjANTL2FMykB+Ue9OjIZuaFXLc9KeFCscd6CCdFBIqWNADzSQADvzVpUBFSIhVMN6U4g9BT8Ac5zRk9OMelAxBH8oyKQ8HAFTZpNuDlqRNxi8j3pHz2605uKi/iyKBDenNU9Ql2xnbVx+47dqz9RiLQnHJpG1NK6OO1K6JmJOVA6VhJqqm7Kpw2ea2NcjkVG2jOQeK4Ny1tOC6NnmqpRU7mmKrula2x6fY3CMgKtlsdq1ba73ZSThh0rzLQdVaGUAt8pPGTXY290JUOTj0PrU6wdpFQaqq6Nm7n2rwckVRW6ZDnrxkiqM16IlAfknPQ1lSawVlZUx90jHemjTlUTqo9SH3SMVI1wjLuDDFcXYar5smyduDwGrUaXYxG75ex603oSoxlsb7zLgfMKj80N0Oax1nLA4YHFWLWXcDzQiZU+pPcSZYelLHJ8wGaglbDLUG8+bnPFWZNGpuqS3G+Xmq0L8DNaFqVKZ70GY9jt4qtdN8hA6mp5SKhbk5NDBO2pmQWzeeWbvWnKu1AMdqEAzT3O4YpJaEyk5MplAYznrWFd/u9RiOcbuK6J1wprmNeUxyRyDOVNUiGbsa5GT1q1HjAqhbvuhQ+oq3G3TNAblpQOpqTYvYVAM4z2qUOMdaRJj6bCFj56960o0xiq8QwBgc96sBvlpHa3zErDBAFKpzxWXc3jK+0VAbqXYeePSpuXGi5I31ILDFTRnnk9Kw9PuWllKkYxyK24huGSKLkzhy6MtRgdc5qVTk9KrxkYHHFWMnK7FyPWgwJIxtOPWrI4HJNRxg46fNUxy3BpEsjYelPC8ZzUioMYpxAAxQFxq4xz0prOM9KUZBwKaU3AkmgdxHlHSo/M29eKjuMRpuJ+U96x7q+HzDcDj05pXsawp8yNpmRhncKjmUFSp6VzTXwU53EGhtWdVDZbA6mhTRaoPdEmo2S/MrdD0NcfrelM4JUc+vrXVnURdoR5h/EVWLhyQcEetCdndGrp80bSR5y1m0RxjBB61r6bcvPamNXxKh/Ot3Ura1KFnwvuKw7BrWC74LEA5Bx1q5vmWpzxTg/dC8d2gCgneDg/WqCbw247dynBz1rfkiWVmdQuOo5HNU74QpbACLEgbO7PeiOhrK7RniMLcBwMq3p2rRjmMfDH5RTxDG6xuowzfeqnLG0cxjLA7TnGeooepMfd1Lb3RXBQ5J7VftJjtBz1rDjHnyfKMKDkexq+j7WA2/MOp9aEaRnzaM2mYMAc1U84+eE9aI5AY+TVV5Ntwueh71ZhUdmbPmbYxh9x+laluSsa564rADgFASADW2r/uxt9KQlqSSP70wNu4FQzPhOTiq9tcfMQTSKdOyuaEec05ic5pkLAnOakHzNig5nuO25HPSsXV7cSxsMdq2mPYdqpXIGCTVEyM7SpN1uAeq8GtRDkDisfTxseRh91m/KtiP7tMSJVY4qZUDDmoV4qQE1IFNWGOKcH4INRL0qZFBFB03M25OXJXkioMM3atKeA5+UVFFbOGBOaykd0Ki5SxpkQBz/F/StmM4xVG2iIPB4q9HGTTRzTld3LEa5+b17VbgAwKqxqQOKsw7sknv2oMZFoDDVNEBkk1Aue9WUGQMdKDMUsAelNdwfujkUbATT0Cgn5c0wG4PBxVa5uVgBLYq2xGMlcVyfiG7KByMZHQZ60GlKHO7MXVdYhIZWYDaOgNcq2oKkzFsYPTbWDf3DPOWDEH19KrPLI3ylsnGaShzHVzKnojpjexPIoSRdzHjcwH86bfSTQ7lIxxyQQR+YrlQHYgHZkdjVyBZHlVYycqDu3E+lDhYmNVt6GglyysDnqPWr0d26gYPHvWOSTtIUDFX4fmVaybOyL5lqXmMdwP3gBGOK5qcIl/Ii424roxCTE7AkACuRlim+3M6nrnr6VvDVHHW0lob+jbJIGjBG4DK0l1ErKVYHOPQ9ay7QvE3m9icADtW41wrxrKDukA6etMlNvYoW2+GNFdTtzkH1q1fxp5azBQfM6+op4kW9eODyxGn16Goiux5ba4Yrt7+v0pIiTKPCNuT7rdRT0kKAODye1SND5sX7vqOT9Kh2AfMDx2HpVGalqWoJhjDZz39qr38wj2sScZqJJSsrqOc1FfybogGHcCriRUlc1bKQXbA87Vroo5PkAAwBWBpC7EAAwO4rejYBeamRUZaFW/l688Cq9keQ56GnXb7g2BUNkWPykcZ4rN7nS5e6b0P3QRT4WJlz2qujFUAqWLP51ZxvctDlj6Gql7hYyfarCkjrWXqcmUKZ5IpoTYaMizWki99xIqxCSh2t1B5rN8L3kbPJbZG9DW/dW5IDqOe9MkaOFyacHA71XRieDTzUgRxoCKnhAGaap6YFPOeMDrQzcew3HgUoXHWnxrxyKftB4IqCoyI40OeKtxgBeTn2pqJ8vB4pyqMHnmgTZaB2qCOnpUsTcketU48k4bnFXYxk9c+lIRYDAYyM1YTJUHOT2qsM8Y59qtQjcxI6UybjgO4py8HmpGUYxnrQMAnH50yWR3H+rYAc4rh/E6boxyST1GK713GzAHJ61y+t2om3DGD2qZG2HkeYyRYlwV47iq5tv3gC9c9c10l1ZOWxsPXnikh0wswITn6VKm1ojqcEznF06eVjtDEetbNjps0W0OD+XWuy0zTgVGVAXvxWr9hiHPXFU7yWpkpRps4tdIU4XbyasJpezjbxXTtCq9hmopMA44NLkQ/bvoc5LC0QKN0Ncjq8RikZScEnAr0a7iWVDxg+tcjrFg06uvVh19quOgpe+jl7acJGyPuODWmgjBDnOMAgetZb27QSos7cr2A5IrctYy4Xd89vjeMdR7VTMotx0LFiYImaUQs7NwDn7tEjyTymSRFdIx9MioXAKF4N6Rj5gD3qAXLFCuWwecUh3vuT2wCCQoV5JPXpx0qqSGYL+tRRAqQzAgH1qe2h8yXzC22NTmmZW1IFTFwQVPPeqd7wPo2a1XYzOxAwSc1WuLYlTuq4mUy/pU4kiU+361srJgDPNcro8hWRoz1XtXRRtuwO9KSLi1YlkjLHK9PSnRR7CDT1PAxTX5PWlYfO3oWYss49qtFsDpVa3yE5HJqQtng0hDnkwpqlFE00ruRlR0p8xJIAPWtOCARwcDkimjOR5Yt2+l+KJOoBevV7KcXECOCCDzXA+KNI+1XfnRD94p5FdL4aZ0s1R+q8Grm01oRTjKLbZtXFqeZIxye1VQezdRV+OU461HIiO2SKzNCqMA+1SIecmmOp7U+E8gUje5ZGSowKkQHJLciow2wetG7PIPFSIkJA6dakiBPWol56GrEYAHPWgGSKmCpA5PWpUJDYHWmKw4IqZTzmgm7J1HQ4471ZQnjGT9O1Qwk8ZwRVgAk9KCR6OWBUjHv3qVEIHNRgAPxUoJ6A/jVANdeD2rOuLTzHyXINXsPvwx4oZfUc9qkpPl2MabT41Uc5psVmi1q7cr81RuvBwKVi/aMqooHAOAKeG5x2qObgcdKhEu3+GgNySYDPNVCpJJIonuAT0qFrjg0WGiObIzWRqMQd8J/rMZI6frWrvyc0joGA4GQevtTLjLlOQnsluPMkd2RtuBgZwazrG5awmFvMoeLBwx6g4611N7CY3LoMg9RWbPYxXMbtt5FUE1f3kZksk2CA6mMjge1Ri4jjYo6jOOuKWW3kjADZZcY+lDxAkLKOCMhqCbhIFaMHcXUnjJ6VNMuyPy4htAH51Qit2W6jVSSC1ad2SHb/ZbbiqRA2BCq5bGaJuRnHFVVkkZ+OlXSuVwfSqMpx1MF3+z36sPutwa6C3m3KKxdUhwu4DpUml3O5ACc44q3qjBT5ZWOgVvl4PzVPChYgmqcBBAq5FJtxWZtzFzGF4oC8ZzTElJxxxQ7kuEX8aQXLFnCHm3dQOlaMowD2GKgtQI0GOpqSVtwIz2oEYcy4uWPY96vQouzjg+1RXsWyFX75p1q+QB7VQ7lpWKjrSiQmm5FMzipJ5ifn60i4D9efSm7SRxUiR8e9I2Q5zlDimozKmMVLEoXrzUu1WOaRoiGJiWGOvpV9H9RVZFw3AqwqNxxUktkqjjPepQfl461GMqvTJqZBlcucn0oAkgBLDJrQQ/Ljv3rOjOH4FWomO/HemjN7kwPzVIsgHemhQ39aXyh6UxjzICQRULyE59acVIPFDJjnFSBENxzk0xyRTnGfpUUoXjH40MZBcNhRgVQlfP1q1OwIKj86pvGD3zQikVHkG/mmEjOc0XEbFwzHIHpUZwSMjBFUMsIAfpTm4IxUSE9qmUYGOuakUpEDxA5yM5rIwUuZExgYzW3IdoNY96hjl81OcjmqKpyvdGdOiuCpz+dZN15QYgMxIGOTWvdyjyWZfQ1i6PcRy3bLKNysO470DasWdLhPlmaQ5Y8AelTOmRjqavzYCADAA6ADFMijBU5pxM27FKOADnFSEYFWdo7VHIowaozk76mXfJujI71gWpeOVsdjXTXK5BrFSIee+BxWkTjr6WaNSyuMhQTWhHLyOay4rclCVPIqRJGiOHHFS0FOrc2lkOOOTVq3Ug72HJrIgmAXIrQhuQwAzSOiMjU39MflTicjgYqkkhNWlbK1Jdxt4C8BUcgCqNpL8o5wQMVffJUj1rHZvKmcdBVCNVHyKVnGaqQyZXOakJzQRc0n68U+POaZkbjU0eMVmdQ58DGKEDEcU8rnHpUigL1qRXFUYwRUgcmgEY4FMAO7NAlrqWFzj0p4+n41HGDipB0oKJ4wM5J6U9WG9c+vNQBTuznipEPTAzVIze5oROCTg8Z6VMnAOOaqwDGMd6lyR+eKBj2ba3I6UwyAqSSaHwcnFV5CUUZqREF5cLEBg8jtWRNqDsSF6VBrFwWkwp61lPI2Qeo+tQ5HVSgramnLdkE7jWdLfOsnGcfWs64vAB8wINU5LxVblgDQmzXlia7aiwb+LNMF9g5bOayhcq+CpBqKSXJ607j9nE6CDUADk9K0I75HXgg1xf2oqdp6VfsHcjJGPShS1JlQT1Omd99ZupHENWrYNsBaor+PfCRWhhBWnY5+7/AOPVh0+U5rmdIMkt8qx9jng9q651DRFGPB4NQLbpDjyY1XbwNox+dUipr3ifLNIFznFW1QYAFR6fEx3M9XCgHSkYTKuzBqGRRzVxlzVeQc0zNmfOvWs61UG6ZSOtatyPlOKo2if6dVo5K+xetrciQjGKlubMMPmXB9RWm1uHiDxj5gOat26JPGo4z0qW2cidjj5bd4G4yVqe2m6c10N5p+ATjIrFuLIo25AcUcx0U61ty1BLkdauxyDHJrCUvEeQatwTZFM6FK+pq7gRgGs+/TI3jr3qeOQY60OAwNAXKVvIematB+OtZ11G1vJlehqWKXK8mgVzp1QAtk80sfXipT16UhUDp1rM64skLgL1oRix5qq5OcVPGTtqSrFkkU9f1qFeRzT0we3NBJZHC5NIpP4U3B49KlTGOtAmSKQRgGlLBXHv2qNAc8dKeflIyKoguxPnGTk9qkwzdPrmqkS7utW4genXg96CiVAMYYZNVdRASPkGrkO0EEg9PWmXUatGwwTmgUXqeeatK4mkByAG4+lZjXJKBd1dTrVl5vCrhl71ystkysQV+YVzvc9OFrFO7kZjngseh7CsrVmVFjI2sx4PbFbFxZyEjaGzWf8A2M01w0k7FueBWlMxqRk3oVbLeo56VoJGxG7mtG3sByioBgelXrbTXByRxQ0bRkorUxRbEkZGK2tPtCSvpWjbadj74q9HEsfAFCjqZVK62QzywFA6UySMMOnFTEHPNIFzx61ocrlqY9xYgksh5qJbLHLP+FbLpgEGoHXtnimU6jK6xgAbegpdvy81Kq44xSlCOooMWyo4AX3qpJ1OavSDk4qpKvNMTKU4G01lsSk6kdc81sTLhTWXIMTKccZqjmraxOv08b7dSemOaaw+zzblPyt+lGksUhVuoIq5OgdCQOD0pM4SxCVlQZwc1Dd2IYDaBVaznMT7HOM9K2IzuGepqRnL3diVJ+XNZjWzA5GRXdSxLIOQKzUskcsuMHNFxqckcrmSM4waminwRk81vXWlfKSBkVlzWYjOSp4quY1jVK8rpIPmIqowAPB4q69ruGVBqE2jZ70XK9qjpHJHekjbOdxpkwyODTVYgYqT04ljcAeakX1FQYPBxUyvggEUirkyE7TUsJH41EDkcCliznpzQSW8jHNJkHikAPGadtz0pCJ0OFwDxSgMTnFRAYHvUitximTJFiNuvpjFTo46E1VTqCfy9amXG/digm5ejI2DaOc9fahtx6EU0NgABc05Rnk8fjQIrXNqrrk/ePU1iy6em8kpn3ro5D6YqCQY54qXG5tCrKJzf2BQSfLP40w6agPC4zW85GD0qBxkcGmoJIbrNmbHZogJwM04pjgAVcKHGDUTxEc0C5m9yFRgZz+FNYg9OtPAxnNMI4JpkkJ5OM0FdvPenbMHJpB3piGNyOaj289KlK5OaGXigCFgCeKY2cHPWntTWOFJoJKkmcEk8VXlHHvVt+R04qsw4OaYmU5+QayboEfWtiYcGsy7XPSqMJ7G/wCHpg8AVzyK2WXy2wfuHvXK6BLtbGe9dcNssQGfmFQzha1M65iDNuHBHSrNhcll2t94dacU6giqk8ZT94nUdRQM2l5Wqq8XBApbG6WaIc8ikYYuQaQi5jK81DJbJIDkDmn7wBSGbafagkYLCLYAQBUf2CHqMVK9wApqjNfBSAKAIGI2e9MB56U5jt60A57cUz3ESx/L708nceBSRjPXpUigAcdaQAT8uO9SwnHWmDOelSpx1FAibIIHNSqflxUIbdwBVhANvvQA7GFz3p4xtBIpU5XgZzQq7QM0CFGOmOasRcNyDg+1RY3E8VPGMAEAYHvTM3uWVbA2qM470MG68Z9DTFIySTinlgwxnigoZgE8kZphXJwxqU8H2pGx170AUpU+bA5qN1OKtuMjOKruMHrSGRNTD0qRuDUTjIJoHcgYjJ4qAkEnmpXUjNQ9zQAw5JxT/LwvWmqcuMVORwKYivs2gmmk8VZcZHFQMMc0CID15qJ/SpnPPSopOTTJuRNjFV5F4JqaQ8Go2zt5qhFGXqc1nXK/LWjPyTiqM/QUESIdKm8u6ZCe9dhbSnaCK4GdmhuFZe55rrtKuhNEuT0FJnDLc2pB5ihh2qMqHU8dO1EEmKe48tgy8g9akkzXD2kwkQEqeo9KtNdo7K4qeVFbhuVNUjYjzCASFPSgkne6GOtQ/acn5RmpEsB/ESR6VYSyVcFKQyjcxXLxkoSPaorWLCnzgS2a12LoMEZFMPlSc9DQIpY3c96OnBPFOYdxUfJNM9wmDZHy1IjfnUMfANKGxSEWwR0PWpAOOKrhgQOasxEYAoESxKMEZ5qZF96jXAyakHI4oJuSL1x2pXfdyO1NRMqTTohg4NMBYWI61Y3cfLUHJBC1OudoJ7UEsfGTnJHFTggj5QAajR+OlOyeuOKAuSEZGCRmopFxyDSk/MeKSVjs4/KgZESdoGc1Gw45qXPHNRE5PFIVyF8Dg1DIDg+lSyj5hUTkj6UDIHXrzUBUc81ZYVHtyeelAyKOMZznmpSAD1oK+lIRgZzzTC4j8KarknnNTZHQ01l9KYmU5CQ1RnJNTXA5461BkiqJGtgg+tQOcnFT8ck1C+BkmgCjN8qk1mzygjA61o3hAAANZrGEn5D7GgbWhVuU3FTV6wL27gg/LUDgEZrUsYRLFg9aTPOqfEa9vMGRSDWjDIHXDCudAa2cDJ2mtK2nygOaRBecYO0nrSZ6qetNeTenHX1qASneo7k80mItwSZODU2T+FU0B88r0pZpmR9ickdamwy3NIqrgnmqMm8tlV4qS0hd23THPtWksAKjAApkmTg7eQKiIqQtleuajxlqZ7YISOKei560gTBBq1EgIoERgYIq1H2oaPjIFIMg0BcnBzUgOB702IZ61N5dBI5WwOKeiluQM+1RdOAM1bhYAAcigzbERB2HNTKBgikAwCeOuKUjJOO9AxvIJHP51Kp471ER8xx2qZBlaYAyk88YpjLtGakIKrkVF82eTkUihmMA+9Rhcnjp3qcnjpTM/wB4YoIZBKnNROAankIqFyPWgcWQ455pAB3pxGaMcY/WgoQKOtQyYzUjHbzmoXx1NBKGHGc9qazYFNOefSmMGxTHIhlOWqB6lbOaYymqJISe1RykVMwxVS4IwecUDWpjapKUV3z0OMVzSXrrK+ASu6tzVMS28+DyOa5mzAVAz9DzVKPViqNrQ3ra4EkoQ8ZGa6TSDgYNcfAjIyzt68fSt/TtQKdqzkcVXc6qW2WVORzWXKhtX5ztNNOpzOuIwaqXE11KvzChGRqQXI4xUkmWIZO1c0JbqJj8mRWlaXz4AkU+9Mk3oJ1fG44apmKD5iQTWTFLE/JbFWYzHkFmqQNGJssMVeA4GTisqO8jQYXH1pxvQerAUhFNiVNKhwcmnyKcZ60wAAVR7TkWAdwGBViLpVWLqKmD7aCLlsMNuM0hXJ4qurZ5zVmM5oGSxHipQ2VqNFA+lKMA0BcnQZ5p+SB1pqH0qVWGcGixI5XyAPb9alGQPemYG30pokyCvWgB6uNzA8E1KhPXPy1EEUlTipekeB+VMQpbKgCk+XHXmmFjxkdaaRk8jHvSGPPB4qGXk1IOOh5ppBbPPSgCs/SoGHoOatsMdqhJGelArlckjrSF/SpHOTjHFRuAB70WGRyElhTGweKe4J6VCxIPNADZM9qikbC1IzZFVpW4OaoT3Ii2TSM3vTc0xz60D5QkYY61nahJttyQeanuJAsZPftWHcO83AJxQjSEEtSnGDLFMpOcis22hUna3BU4ArYWIRHIPXrWWn/H+UB/iFWzOfxF8xApt7Cr+kRBjgjPNZ12whmO2QlTV/QpfmyT3qDjqo6e2s1HO3mrotFxnAot2DKKtZ+WoMDLmtUyflFNWyXGSo+lXG+aTipggAoEZTWingAD6VJJaLFDubPPStGKMM/Tmluo1chewpAcxNBMX/dFgK0rLSpJIt0rnP1rTjtiSFArTSBQgBGCKoiRz+SaT2pFbGM0Mcc1R7EiQHA96XdmoFbLYqZR60DiSQsd3tVuOTGKqr8oqWM8igUi4HAxk0vBPAqvnNSRKV980EltR8oINSxn1qtuwCPypY3JOPWgC6xwvSmxsGOB1qFWJJBNSLgMCKAJ1bCgHrTg+e9RdRTgfUUCZLkpnHzDtUFxOIuX49qlRvUYqGVEZvmGTQND43V1DAc0/jcRnrUZACccYoJJIFABJ04qq3B5qZwcVBIBg5PNBIOF25JqLbnmoy5HU015SRwKCgc4OKhk6Zp/JGTUbHnHagdyGRhniq8h9ancd6gkFBL3K7e1Q3MnlqSeuKnPWq1wocEGkzWFjKmuDIOTisq/vhEQgxurRu18tm9AOK5C4Z57hmyODinE0qSVtC9b3cnmEs2U54qIM3nGRD1qKRWjgAjA3EcirGmWztZsrk7+oqzmk3cslAyqWJJIyfar2lDZNx93tVB3khAjxuJAzVnSpGJdjng1DMKp3NnJmMc9qvB8rxXO2M7bK0ILgkc1BzFuM/vKtHkVQjbDZNWQ/FMC3bgBiTTYyGlPPSiBvlJ9qp2c2bpweeelSI2LNC0x5HFWbpgpTI5xUWnBTMx6EVHqkmJlAPaqRm9znG5ximt9aYWAPXmkBJNUezcsQgYxVlBkiqUbEOc9KuRHjPagCRuKerAConNPUbsYoGSpgkc8VYJK4qGMYqVfQ96RLHj5qUAZpoOB7U4EbT60CsPUHGc/Wp4zgYIzVVGOcevNWlwR70xEisUzjkelIz5YZHFJj3pC2OKAJUkHY/hTiwLH1qvnGCOlSjqTQAr4KnnFNUkDmkZhUZfsDQASPzULnIpshOfakDDGKAEIBphAH1p7DuelGRtoEQPkLUTEVNJnB54qu1BJDI2GxVd3BJ5qS471kNflrjylQ/XFMcFfUuEnNMfpz1p44A96imYLk0GkTC1qbCswHAFcwn3iQuecGupuQHLlucc49q5uedZL2YRrsjzwv4UIurpZDmVVc1JHKoAVXIqJsEcD5u9Pi2x8bASe9BM1oT3jIBG+SeOasaTzvDZORmqrxlowdynP8Iq3p58q52eopM5Kp1umW4MXIqxJb7GytTaSN0I4qWdfnHpUnMUSGUiphIcVLNGMDFQ454pgaNqf3LH0FZenZa8kY8DJrVjwlqze1Z2kkM8hI71II6XSlPls2Cc1S1Vh9oxg1o2BZYBtYYrO1ZT9p+ooMupzfU06Pg0nFSKABmtD1iVDu4xzUoQ461DG4yKnDj1pDTAjpzVhGDAVCOalTpxQXcnjbAxipdxPQVXQ+vSpFY5GKkROig85p4XDDPSmKeRinfNj0oBjXyG49f0qeNiGB7VAzHIGc0qswI4qiS5vycd6a3HJpobgZ4pXbOD6UCHA5QAikVsgik3E8YoYgdKBhuwDTGbB6U5mGOKhOWYt2oEBbPakyM4p2096YVyeKBA/PFRnIp7tgVEWGaCRrNUDnmrBXvVeXjJ70wexTnJOcdaq7F3ElRn1q3KOcmomWgcJW0I8Z5qC5BZCB6VaxxUMg60Gi7nPNkTSAn+HFc1dxvFMd3BJrsLmHY5k25U1j6vbo8TygYKjPNNFz94yxKq8AZJ7ipA205BJPvTLSA+WHYDrirIg+ZmDBRjp60zJyuwTIbOANwyRVvTgfNBPU1BEC2QV7YzVmwz5qbhjFSYVNjvdHX91+FOuf9aBRpHMIxS3X+vrNbnKI+MDNVv4+OlWH5AqFMbxVMRcn4tAB3FVtNh2Ak96uypuiQdqfHGFHFQBp2CqYARVHUxun61csTthPtVW+b97kiqM3uctnJpFYnINCUuMN71Z6qJEbaOakDE1GOR0pwOD7Uii5GQQOeanHTjrVRTgCpVk96AJ1BIxUq5Axiqu7jmp45DgelA+YnjbJ96nByKqlwOlCuSCO9AtydsDmnBiF6VGhPQinD3oELvOfenqSBwfxqPHIIp/Y+tAh28jnqaUEt1oC/LmjIxweaBgTgUxDluaGJpY9uDzQK4rHjjpTAQM560pOM1Gx9KCRrZJNNVcZHY0pPFNLYFAAScGq0pOamZsKfWqkr80CYxx1HXNQt94CpCcjimEetMIjT0qnfXIgQZ79KuN0rO1K2a4xtO3Heg2i11Kf2oTI6FcAd6yr5la1cMflI5rSEBghk+bJI61jXW9raQHsKpltq2hRguFCsTgcjA/CrhkzszjnrWWIy2CMdcgDvxRJO6vkdBRExexqTSBWXYOKmsmZ7hNx5BrMjdiR3zzWlZviTI6ihmFT4T0LRWHkCn3f/HxWZoF4GiwTitC5YNJkHNZLc5ReoqIDEg+tKrUjdc1QFm5uBCFJNS206zL8rCsbXpWSyDjqBWV4XvJZizOTtzxU2JO+szjIzzTbxTvGSKpWVyrMc8VYmlDMOM0IlnJqRnAqQN8wFFFWemSJ0pTRRSLQB93B6VIooooLRZVsYFSAfLmiiglhkDkVPA24nFFFAFlQcnmmSNiiigkmhOQDTyuXJoooENLEHFNPJxRRQNils4FNY7elFFBIwsc0maKKAEY4GahkJxmiigZEzHIqu5y1FFMiQwdaRqKKCojH+6aryNhSaKKBnPalesZCgGBVUfNbSE/3KKKpmr2MaH5skkgAdqhkXO7k/jRRRExZbiHyqP9mrtmv71uewoopswq7G7Z7oQCprShu3OM0UVmcxbMxwKUzE8UUUFC3MQubR1bsKwtLX7OzovTNFFBDOi09gUJA5q20hoooM5H/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized blistering, crusted erosions, and extensive areas of denudation in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15568=[""].join("\n");
var outline_f15_13_15568=null;
var title_f15_13_15569="Gastric MALT lymphoma UGI";
var content_f15_13_15569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric marginal zone (MALT) lymphoma barium radiographs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two air contrast upper gastrointestinal barium radiographs demonstrate diffuse nodular infiltration of the entire gastric body in a patient with a marginal zone (MALT) lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15569=[""].join("\n");
var outline_f15_13_15569=null;
var title_f15_13_15570="Neb or MDI use with NPPV";
var content_f15_13_15570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Aerosolized medications, either by nebulizer or MDI, can be administered during NPPV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15570=[""].join("\n");
var outline_f15_13_15570=null;
var title_f15_13_15571="The 3 incontinence questions";
var content_f15_13_15571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    The 3 incontinence questions (3IQ)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 669px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med 2006; 144:715. Copyright &copy; 2006 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15571=[""].join("\n");
var outline_f15_13_15571=null;
var title_f15_13_15572="Parotid gl facial nerve";
var content_f15_13_15572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Parotid gland and the facial nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relationship of the facial nerve and the parotid gland.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15572=[""].join("\n");
var outline_f15_13_15572=null;
var title_f15_13_15573="Auricular biopsy in RPC";
var content_f15_13_15573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auricular biopsy in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Auricular biopsy of an early active lesional site in a patient with relapsing polychondritis. Histopathology reveals a pleomorphic cellular infiltrate at the chondro-dermal junction in conjunction with proteoglycan depletion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome H Herman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15573=[""].join("\n");
var outline_f15_13_15573=null;
var title_f15_13_15574="Dihydroergotamine: Drug information";
var content_f15_13_15574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dihydroergotamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/36/8773?source=see_link\">",
"    see \"Dihydroergotamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=see_link\">",
"    see \"Dihydroergotamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      D.H.E. 45&reg;;",
"     </li>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine, cluster headache:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     1 mg at first sign of headache; repeat hourly up to a maximum dose of 2 mg/day; maximum dose: 6 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intranasal:",
"     </i>",
"     1 spray (0.5 mg) of nasal spray should be administered into each nostril; if needed, repeat after 15 minutes, up to a total of 4 sprays (2 mg).",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 6 sprays (3 mg) in a 24-hour period and no more than 8 sprays (4 mg) in a week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intractable migraine (status migrainosus; &gt;72 hours):",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     Raskin protocol (unlabeled dosing): Initial test dose: 0.5 mg (following premedication with metoclopramide); subsequent dosing is titrated (range: 0.2-1 mg) every 8 hours for 2-3 days and administered with or without metoclopramide based on response and tolerance (Raskin, 1986; Raskin,  1990).",
"     <b>",
"      Note:",
"     </b>",
"     Some clinicians use modified versions of this protocol, with additional adjunctive medications and/or alternate antiemetic agents.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Patients &gt;65 years of age were not included in controlled clinical studies.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F160470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F160471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage reductions are probably necessary but specific guidelines are not available; contraindicated in severe hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate: 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     D.H.E. 45&reg;: 1 mg/mL (1 mL) [contains ethanol 6.2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as mesylate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migranal&reg;: 4 mg/mL (1 mL) [contains caffeine 10 mg/mL; 0.5 mg/spray]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intranasal: Prior to administration of nasal spray, the nasal spray applicator must be primed (pumped 4 times); in order to let the drug be absorbed through the skin in the nose, patients should not inhale deeply through the nose while spraying or immediately after spraying; for best results, treatment should be initiated at the first symptom or sign of an attack; however, nasal spray can be used at any stage of a migraine attack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., SubQ: May administer by intramuscular or subcutaneous injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer slowly over 2-3 minutes (Raskin protocol)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of migraine headache with or without aura; injection also indicated for treatment of cluster headaches",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F160505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct for DVT prophylaxis for hip surgery, for orthostatic hypotension, xerostomia secondary to antidepressant use, and pelvic congestion with pain",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Nasal spray: Respiratory: Rhinitis (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Nasal spray:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4%), somnolence (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), taste disturbance (8%), vomiting (4%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (1%), stiffness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Injection and nasal spray: Cerebral hemorrhage, coronary artery vasospasm, dyspnea, hypertension, MI, paresthesia, peripheral cyanosis, peripheral ischemia, stroke, subarachnoid hemorrhage, ventricular fibrillation, ventricular tachycardia. Pleural and retroperitoneal fibrosis have been reported following prolonged use of the injection; cardiac valvular fibrosis has been associated with ergot alkaloids.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dihydroergotamine or any component of the formulation; uncontrolled hypertension, ischemic heart disease, angina pectoris, history of MI, silent ischemia, or coronary artery vasospasm including Prinzmetal's angina; hemiplegic or basilar migraine; peripheral vascular disease; sepsis; severe hepatic or renal dysfunction; following vascular surgery; avoid use within 24 hours of sumatriptan, zolmitriptan, other serotonin agonists, or ergot-like agents; avoid during or within 2 weeks of discontinuing MAO inhibitors; concurrent use of peripheral and central vasoconstrictors; ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); pregnancy, breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Vasospasm or vasoconstriction can occur, possibly resulting in decreased cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may also lead to ischemic colitis, intermittent claudication, aggravation of angina, or precipitation of MI. Do not use is any patient at risk or predisposed to vascular effects of ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have also occurred (in some cases resulted in fatalities) following use of the injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Do not give to patients with risk factors for CAD until a cardiovascular evaluation has been performed; if evaluation is satisfactory, the healthcare provider should administer the first dose and cardiovascular status should be periodically evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors:",
"     <b>",
"      [U.S. Boxed Warning]: Ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); concomitant use associated with an increased risk of vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with extreme caution or avoid use in the elderly; due to vasoconstrictive properties and cardiovascular adverse effects associated with ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migranal&reg; Nasal Spray: Local irritation to nose and throat (usually transient and mild-moderate in severity) can occur; long-term consequences on nasal or respiratory mucosa have not been extensively evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Dihydroergotamine. Management: Avoid dihydroergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dihydroergotamine is oxytocic and should not be used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F160450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergot derivatives inhibit prolactin and it is known that ergotamine is excreted in breast milk (vomiting, diarrhea, weak pulse, and unstable blood pressure have been reported in nursing infants). It is not known if dihydroergotamine would also cause these effects, however, it is likely that it is excreted in human breast milk. Do not use in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F160448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (D.H.E. 45 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $215.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dihydroergotamine Mesylate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $78.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Migranal Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $199.59",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F160441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimum concentration for vasoconstriction is reportedly 0.06 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cervasal (BG);",
"     </li>",
"     <li>",
"      Dergott (JP);",
"     </li>",
"     <li>",
"      Detemes Retard (AT);",
"     </li>",
"     <li>",
"      Detms (LU);",
"     </li>",
"     <li>",
"      DH-Ergotamin (PL);",
"     </li>",
"     <li>",
"      DHT (AR);",
"     </li>",
"     <li>",
"      Diergospray (FR);",
"     </li>",
"     <li>",
"      Digalo (TW);",
"     </li>",
"     <li>",
"      Dihydergot (AU, BE, BF, BJ, BR, CH, CI, CZ, ES, ET, GH, GM, GN, GR, ID, IL, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NL, NO, PE, SC, SD, SL, SN, TN, TR, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dihydergot Sandoz (AT);",
"     </li>",
"     <li>",
"      Dihydroergotamin &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Dihydroergotaminum Methansulfonicum (PL);",
"     </li>",
"     <li>",
"      Dihydroergotaminum Tartaricum (PL);",
"     </li>",
"     <li>",
"      Ditamin (HR, PL);",
"     </li>",
"     <li>",
"      Dystonal (BE);",
"     </li>",
"     <li>",
"      Ergotamina (PY);",
"     </li>",
"     <li>",
"      Ergovasan (AT);",
"     </li>",
"     <li>",
"      Ikaran (FR, LU);",
"     </li>",
"     <li>",
"      Ikaran LP (FR);",
"     </li>",
"     <li>",
"      Migranal (GB);",
"     </li>",
"     <li>",
"      Migranil (IN);",
"     </li>",
"     <li>",
"      Neomigran (HU, PL);",
"     </li>",
"     <li>",
"      Orstanorm (FI, SE);",
"     </li>",
"     <li>",
"      Parsel (MX);",
"     </li>",
"     <li>",
"      Rayor (TW);",
"     </li>",
"     <li>",
"      Seglor (AR, FR, IT, LU, TW);",
"     </li>",
"     <li>",
"      Seglor Retard (PT);",
"     </li>",
"     <li>",
"      Tamik (FR);",
"     </li>",
"     <li>",
"      Tenuatina (ES);",
"     </li>",
"     <li>",
"      Tonopan (MX);",
"     </li>",
"     <li>",
"      Verladyn (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergot alkaloid alpha-adrenergic blocker directly stimulates vascular smooth muscle to vasoconstrict peripheral and cerebral vessels; also has effects on serotonin receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~800 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~9-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 24 minutes; I.V.: 1-2 minutes; Intranasal: 30-60 minutes; SubQ 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (6% to 7% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskin NH, \"Repetitive Intravenous Dihydroergotamine as Therapy for Intractable Migraine,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1986, 36(7):995-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/13/15574/abstract-text/3520384/pubmed\" id=\"3520384\" target=\"_blank\">",
"        3520384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskin NH, \"Treatment of Status Migrainosus: The American Experience,\"",
"      <i>",
"       Headache",
"      </i>",
"      , 1990, 30(Suppl 2):550-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/13/15574/abstract-text/2272823/pubmed\" id=\"2272823\" target=\"_blank\">",
"        2272823",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saper JR and Silberstein S, &ldquo;Pharmacology of Dihydroergotamine and Evidence of Efficacy and Safety in Migraine,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2006, 46(Suppl 4):171-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/13/15574/abstract-text/17078849/pubmed\" id=\"17078849\" target=\"_blank\">",
"        17078849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schran HF and Tse FL, &ldquo;Pharmacokinetics of Dihydroergotamine Following Subcutaneous Administration in Humans,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther Toxicol",
"      </i>",
"      , 1985, 23(1):1-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/13/15574/abstract-text/3988387/pubmed\" id=\"3988387\" target=\"_blank\">",
"        3988387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9363 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15574=[""].join("\n");
var outline_f15_13_15574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708702\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160464\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160465\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160509\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160468\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160469\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160470\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160471\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160440\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160426\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160443\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160505\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160507\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160430\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160503\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160435\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160437\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160449\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160473\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160450\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160448\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160441\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160451\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160429\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160446\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9363|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/36/8773?source=related_link\">",
"      Dihydroergotamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=related_link\">",
"      Dihydroergotamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_13_15575="Microbiology of methicillin-resistant Staphylococcus aureus";
var content_f15_13_15575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology of methicillin-resistant Staphylococcus aureus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15575/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/13/15575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortly after the introduction in 1959 of methicillin, a semisynthetic beta-lactamase resistant penicillin, isolates resistant to this agent were reported. Outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in Europe in the early 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/1\">",
"     1",
"    </a>",
"    ]. Since these original descriptions, MRSA, as well as coagulase negative staphylococci (CoNS), which are commonly resistant to methicillin, have emerged as major nosocomial and community acquired pathogens.",
"   </p>",
"   <p>",
"    Three pandemic MRSA clones have been traced back to the original 1959 MRSA isolates in Denmark and England [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, molecular typing of MRSA strains collected from many geographic areas has revealed that by 2002, five major MRSA clones emerged worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/3\">",
"     3",
"    </a>",
"    ]. The more recent epidemic community-associated MRSA strains appear to have emerged from earlier epidemic clones [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our current understanding of the genetic mechanisms responsible for methicillin resistance will be reviewed here. Virulence determinants for community acquired MRSA are discussed separately, as are mechanisms for S. aureus with reduced susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=see_link\">",
"     \"Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin resistance requires the presence of the mec gene; strains lacking a mec gene are not methicillin resistant. Methicillin resistance is defined in the clinical microbiology laboratory as an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    minimum inhibitory concentration (MIC) &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/7\">",
"     7",
"    </a>",
"    ]. Other methods of detection, such as the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disk or one of several polymerase chain reactions (PCR) to detect the mec gene, are also used. Isolates resistant to oxacillin or methicillin are also resistant to all beta-lactam agents including cephalosporins. MICs of 4 to 8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are considered to represent borderline or low level resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR MECHANISM OF METHICILLIN RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     mec gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, the presence of the mec gene is an absolute requirement for S. aureus to express methicillin resistance. The mec gene is absent from susceptible strains and present in all resistant strains [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The structural component of the mec gene, mecA, encodes the penicillin binding protein 2a (PBP2A) that establishes resistance to methicillin and other semisynthetic penicillinase resistant beta-lactams.",
"   </p>",
"   <p>",
"    The mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    resistance may be different in borderline resistant strains in which the mec gene is not present or is present in a very small resistant subpopulation. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Borderline resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The complete genomes for several strains of MRSA have been published; three classes of pathogenicity islands and diverse possible superantigens have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The mec gene consists of a structural component, mecA, and, in many cases, two regulatory components that control expression of the gene:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      mecR1-mecI is a negative regulator of mecA transcription. Mutations in this set of genes results in more highly resistant strains.",
"     </li>",
"     <li>",
"      The beta-lactamase genes &mdash; blaI, blaRI, and blaZ &mdash; control expression of beta-lactamase and because of sequence similarity to the mecR1-mecI genes also can downregulate mecA gene transcription [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/13\">",
"       13",
"      </a>",
"      ]. However, beta-lactamase produces resistance by a mechanism different from mec. It hydrolyzes the beta-lactam ring. Because this negative regulation is not tightly controlled (eg, it is leaky), expression of resistance following exposure to beta-lactams is relatively rapid. The looser control allows the mec gene to synthesize protein that under conditions of greater regulatory control would not be permitted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these regulatory genes, there are a series of five auxiliary genes that can modify expression of methicillin resistance. These are the fem (factor essential for the expression of methicillin resistance) A to E genes. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'fem genes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Penicillin binding protein 2a",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin binding proteins are peptidase enzymes located in the bacterial membrane that catalyze the transpeptidation reactions of peptidoglycan during cell wall synthesis. MecA encodes penicillin binding protein (PBP) 2a, an inducible protein that establishes resistance to the semisynthetic penicillinase resistant beta-lactams: methicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , and all cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In contrast to the other four PBPs (1-4), PBP2a has a low affinity for beta-lactam antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In susceptible staphylococcal isolates, the beta-lactams covalently bind to PBPs 1-3, thereby inactivating enzyme activity, preventing transpeptidation, and ultimately contributing to bacterial death. PBP2a, with its low affinity for the beta-lactams, can substitute for the enzymatic activity of these PBPs and allow completion of cell wall assembly. The resulting peptidoglycan has a structurally different muropeptide composition, a change that does not appear to affect cellular function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Staphylococcal chromosomal cassette mec (SCCmec)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mec gene is part of a 21 to 67 kb mobile chromosomal element called the staphylococcal cassette chromosome (SCCmec). The majority of healthcare-associated (mostly nosocomial) MRSA clones is associated with SCCmec types I, II, and III and are multidrug resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, most community-associated MRSA (CA-MRSA) strains have type IV or V SCCmec and were formerly susceptible to other antibiotic families; this is no longer the case [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/11,18-22\">",
"     11,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methicillin resistance may reduce the virulence of healthcare-associated MRSA by interfering with agr quorum sensing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/23\">",
"     23",
"    </a>",
"    ]. In one study, healthcare-associated MRSA strains carrying SCCmec type II produced reduced amounts of cytolytic toxins as measured by an in vitro T cell survival assay and in vivo murine bacteremia model. Alteration of the cell wall appeared to affect the agr quorum sensing system resulting in diminished virulence. This effect has not been observed among community-associated MRSA isolates and may help explain the failure of HA-MRSA to spread into the community.",
"   </p>",
"   <p>",
"    Sequencing SCCmec from many MRSA strains has demonstrated at least six SCCmec types (I-VI) that vary in genetic makeup and size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Transfer of SCCmec from MRSA into well-adapted strains of methicillin-susceptible S. aureus (MSSA) has occurred on a number of occasions, resulting in new MRSA isolates that spread rapidly in healthcare institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Origin in coagulase negative staphylococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is believed that the mec gene was acquired from these closely related staphylococcal species via a limited number of genetic events. The mec gene is essentially the same in all staphylococcal species. Several studies point to CoNS as the origin of methicillin resistance in Staphylococcus aureus. Segments of DNA from an insertion sequence found in CoNS (IS 1272) have been identified in MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Insertion sequence elements are DNA segments that encode enzymes that allow for site-specific recombination. In addition, one study reported 88 percent amino acid homology for the MRSA mec gene in S. sciuri, another species of CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of different insertion sequence fragments within the mec gene makes transposition a likely mechanism of transfer for the gene between species [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequencing of the MRSA strain, USA300, an epidemic clone of community-acquired MRSA, has shown that additional virulence and resistance genes have also been acquired from CoNS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/12\">",
"     12",
"    </a>",
"    ]. These genes include molecular variants of enterotoxin Q and K and a mobile element (the arginine catabolic mobile element, ACME) that encodes an arginine deaminase pathway and an oligopeptide permease system. The authors hypothesize these genes enable the strain to evade host immune responses and contribute to its ability to survive and spread in host tissue. The virulence of USA300 appears to be linked to the differential expression of selected virulence determinants that were already present in the progenitor strain (USA500) of USA300 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXPRESSION OF METHICILLIN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the presence in MRSA of the mec gene, the phenotypic expression of methicillin resistance varies. There are three different forms for the expression of methicillin resistance: homogeneous, heterogeneous, and borderline (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Borderline resistance'",
"    </a>",
"    below). Most clinical isolates of MRSA from a given patient are heterogeneous in their expression of methicillin resistance.",
"   </p>",
"   <p>",
"    As an example, under routine growth conditions (37&ordm;C, unsupplemented media), &ge;99.9 percent of MRSA appear to be susceptible to the beta-lactams (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    4",
"    <span class=\"nowrap\">",
"     mcg/mL).",
"    </span>",
"    However, if the cells are grown at 30 to 35&ordm;C or in the presence of 6.5 percent sodium chloride, they become more homogeneously resistant and express beta-lactam resistance at a much higher frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, growth of heterogeneous strains in the presence of a beta-lactam results in the selection of a homogeneous phenotype. Serial passage of these cells in the absence of antibiotic leads to slow reversion back to the heterogeneous state.",
"   </p>",
"   <p>",
"    A similar phenomenon has been observed in experimental endocarditis. Treatment of rabbits infected with MRSA with a beta-lactam results in a greater percentage of the total bacterial population being resistant than in untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/30\">",
"     30",
"    </a>",
"    ]. There was also a correlation between the potential efficacy of the antibiotic and its affinity for binding to PBP2a in vitro.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     fem genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fem genes and other genes are necessary for the homogeneous expression of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/31\">",
"     31",
"    </a>",
"    ]. These auxiliary genes affect different steps in the synthesis of peptidoglycan. Inactivation of these genes can convert a homogeneously resistant strain to a heterogeneous resistant one [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Borderline resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Borderline resistance refers to isolates that are at the margin of resistance with an MIC to methicillin of 4 to 8",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    This type of resistance may be due to one of several mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some strains with borderline resistance possess the mecA gene. In these strains, the resistant subpopulation may be extremely small and therefore more susceptible to beta-lactams.",
"     </li>",
"     <li>",
"      In strains that lack the mecA gene (and therefore PBP2a), there may be alterations in or overexpression of the other PBPs, resulting in reduced affinity for beta-lactams or the availability of more enzyme for peptidoglycan synthesis. Overproduction of beta-lactamase with slow hydrolysis of the beta-lactam antibiotic has also been hypothesized as a potential mechanism for borderline resistance in mecA negative strains [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/29,33,34\">",
"       29,33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LABORATORY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most accurate methods to detect MRSA are polymerase chain reaction (PCR) for detection of the mecA gene and latex agglutination tests for the protein product of mecA, penicillin binding protein 2a [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. When these tests are not available, traditional microbiology laboratory techniques are acceptable, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    -salt agar screening plates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disk diffusion tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rapid testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid testing for detection of MRSA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31654?source=see_link\">",
"     \"Rapid detection of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance cultures are performed at body sites (mostly the anterior nares) that are frequently colonized with MRSA. The majority of patients with asymptomatic MRSA colonization will be detected by screening culture from the anterior nares (sensitivity 73 to 93 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The sensitivity can be increased by also screening open lesions, such as surgical wounds, pressure (decubitus) ulcers, and areas of skin breakdown.",
"   </p>",
"   <p>",
"    In patients without open lesions, a one-year study of multisite screening (nares, rectum, and axilla) found that nares culture alone missed 27 percent of MRSA carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/40\">",
"     40",
"    </a>",
"    ]. Throat swabs also may be helpful. In a screening study of almost 3000 individuals for S. aureus carriage, 37 percent had nasal carriage and 13 percent were colonized only in the throat, increasing the sensitivity of screening by 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/42\">",
"     42",
"    </a>",
"    ]. A similar increase in yield with throat swabs (22 percent) was seen in the small subset of MRSA carriers.",
"   </p>",
"   <p>",
"    Traditional methods used to process surveillance cultures take 48 to 72 hours to yield results. However, newly available techniques shorten the amount of time required to detect MRSA in surveillance cultures. A chromogenic selective agar containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    detects a majority of MRSA isolates within 24 hours, while commercially available real-time PCR tests for mecA can detect MRSA within two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antimicrobial susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, most healthcare-associated MRSA strains were multidrug resistant. Isolates that are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    but remain susceptible to most non-beta-lactam agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ) are usually community-associated MRSA. Such strains should be tested using a confirmatory test such as a mecA probe, PCR assay for mecA, oxacillin-salt agar screening plates, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disk diffusion tests.",
"   </p>",
"   <p>",
"    Antibiotic susceptibility testing for methicillin resistance has been modified to enhance the detection of these isolates, a large number of which are heterogeneously resistant to methicillin. Susceptibility testing now includes use of the more stable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    rather than methicillin disk, incubation at &le;35&ordm;C for 24 rather than 18 hours, and the incorporation of 6.5 percent sodium chloride into the media. It is important to remember that isolates resistant to oxacillin are also resistant to all beta-lactam agents including cephalosporins.",
"   </p>",
"   <p>",
"    Specific recommendations exist for the different methods of susceptibility testing such as automated turbidometric or disk diffusion assays [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/43\">",
"     43",
"    </a>",
"    ]. In the future, it is likely that clinical isolates will be screened for methicillin resistance by polymerase chain reaction (PCR) or with probes specific for segments of the mec gene. Kits for the detection of the mec gene are becoming more common. Alternative approaches including screening with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disks and the MRSA latex agglutination test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15575/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190972270\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shortly after the introduction of methicillin in 1959, isolates resistant to this agent were reported. Outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) infections occurred in Europe in the early 1960s. Since these original descriptions, MRSA, as well as coagulase negative staphylococci (CoNS), which are commonly resistant to methicillin, have emerged as major nosocomial and community acquired pathogens. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methicillin resistance is defined in the clinical microbiology laboratory as an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      minimum inhibitory concentration (MIC) &ge;4",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      Isolates resistant to oxacillin or methicillin are also resistant to all beta-lactam agents including cephalosporins. MICs of 4 to 8",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      are considered to represent borderline or low level resistance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methicillin resistance requires the presence of the mec gene; strains lacking a mec gene are not methicillin resistant. The structural component of the mec gene, mecA, encodes the penicillin binding protein 2a (PBP2A) that establishes resistance to methicillin and other semisynthetic penicillinase resistant beta-lactams. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'mec gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most accurate methods to detect MRSA are polymerase chain reaction (PCR) for detection of the mecA gene and latex agglutination tests for the protein product of mecA, PBP2A. When these tests are not available, traditional microbiology laboratory techniques are acceptable, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      -salt agar screening plates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      disk diffusion tests. Rapid testing for detection of MRSA is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory detection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31654?source=see_link\">",
"       \"Rapid detection of methicillin-resistant Staphylococcus aureus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/1\">",
"      Benner EJ, Kayser FH. Growing clinical significance of methcillin-resistant Staphylococcus aureus. Lancet 1968; 2:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/2\">",
"      Cris&oacute;stomo MI, Westh H, Tomasz A, et al. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc Natl Acad Sci U S A 2001; 98:9865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/3\">",
"      Enright MC, Robinson DA, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002; 99:7687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/4\">",
"      Robinson DA, Kearns AM, Holmes A, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005; 365:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/5\">",
"      Li M, Diep BA, Villaruz AE, et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 2009; 106:5883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/6\">",
"      Francois P, Bento M, Renzi G, et al. Evaluation of three molecular assays for rapid identification of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007; 45:2011.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. M100-S16 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard. Vol 26. No 3. CLSI, Wayne, Pennsylvania, USA, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/8\">",
"      Inglis B, Matthews PR, Stewart PR. The expression in Staphylococcus aureus of cloned DNA encoding methicillin resistance. J Gen Microbiol 1988; 134:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/9\">",
"      Tesch W, Str&auml;ssle A, Berger-B&auml;chi B, et al. Cloning and expression of methicillin resistance from Staphylococcus epidermidis in Staphylococcus carnosus. Antimicrob Agents Chemother 1988; 32:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/10\">",
"      Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001; 357:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/11\">",
"      Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/12\">",
"      Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/13\">",
"      Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. Science 2001; 291:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/14\">",
"      Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 1984; 158:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/15\">",
"      Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/16\">",
"      de Jonge BL, Tomasz A. Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: functional role for penicillin-binding protein 2A in cell wall synthesis. Antimicrob Agents Chemother 1993; 37:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/17\">",
"      Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997; 349:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/18\">",
"      Daum RS, Ito T, Hiramatsu K, et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002; 186:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/19\">",
"      Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/20\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/21\">",
"      Salmenlinna S, Lyytik&auml;inen O, Vuopio-Varkila J. Community-acquired methicillin-resistant Staphylococcus aureus, Finland. Emerg Infect Dis 2002; 8:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/22\">",
"      Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/23\">",
"      Rudkin JK, Edwards AM, Bowden MG, et al. Methicillin resistance reduces the virulence of healthcare-associated methicillin-resistant Staphylococcus aureus by interfering with the agr quorum sensing system. J Infect Dis 2012; 205:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/24\">",
"      Oliveira DC, Tomasz A, de Lencastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist 2001; 7:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/25\">",
"      Ito T, Ma XX, Takeuchi F, et al. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004; 48:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/26\">",
"      Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. Trends Microbiol 1994; 2:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/27\">",
"      Archer GL, Niemeyer DM, Thanassi JA, Pucci MJ. Dissemination among staphylococci of DNA sequences associated with methicillin resistance. Antimicrob Agents Chemother 1994; 38:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/28\">",
"      Wu S, Piscitelli C, de Lencastre H, Tomasz A. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist 1996; 2:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/29\">",
"      Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997; 10:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/30\">",
"      Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis 1990; 162:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/31\">",
"      de Lencastre H, Tomasz A. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/32\">",
"      Berger-B&auml;chi B. Expression of resistance to methicillin. Trends Microbiol 1994; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/33\">",
"      Tomasz A, Drugeon HB, de Lencastre HM, et al. New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity. Antimicrob Agents Chemother 1989; 33:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/34\">",
"      Henze UU, Berger-B&auml;chi B. Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance. Antimicrob Agents Chemother 1995; 39:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/35\">",
"      Warren DK, Liao RS, Merz LR, et al. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol 2004; 42:5578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/36\">",
"      Harbarth S, Masuet-Aumatell C, Schrenzel J, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care 2006; 10:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/37\">",
"      Miller MB, Meyer H, Rogers E, Gilligan PH. Comparison of conventional susceptibility testing, penicillin-binding protein 2a latex agglutination testing, and mecA real-time PCR for detection of oxacillin resistance in Staphylococcus aureus and coagulase-negative Staphylococcus. J Clin Microbiol 2005; 43:3450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/38\">",
"      Sakoulas G, Gold HS, Venkataraman L, et al. Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains. J Clin Microbiol 2001; 39:3946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/39\">",
"      Sanford MD, Widmer AF, Bale MJ, et al. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1994; 19:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/40\">",
"      Eveillard M, de Lassence A, Lancien E, et al. Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect Control Hosp Epidemiol 2006; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/41\">",
"      Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis 2007; 195:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/42\">",
"      Mertz D, Frei R, Jaussi B, et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 2007; 45:475.",
"     </a>",
"    </li>",
"    <li>",
"     National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing; eighth informational supplement. NCCLS document M100-S8. National Committee for Clinical Laboratory Standards, Wayne, PA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15575/abstract/44\">",
"      Felten A, Grandry B, Lagrange PH, Casin I. Evaluation of three techniques for detection of low-level methicillin-resistant Staphylococcus aureus (MRSA): a disk diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-screen latex agglutination test. J Clin Microbiol 2002; 40:2766.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3153 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15575=[""].join("\n");
var outline_f15_13_15575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190972270\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR MECHANISM OF METHICILLIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      mec gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Penicillin binding protein 2a",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Staphylococcal chromosomal cassette mec (SCCmec)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Origin in coagulase negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXPRESSION OF METHICILLIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      fem genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Borderline resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LABORATORY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rapid testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antimicrobial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190972270\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31654?source=related_link\">",
"      Rapid detection of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40758?source=related_link\">",
"      Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_13_15576="Chikungunya fever";
var content_f15_13_15576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chikungunya fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Mary Elizabeth Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15576/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/13/15576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya is an arthropod-borne virus (arbovirus) endemic to West Africa that causes acute febrile polyarthralgia and arthritis. The name chikungunya is derived from a local language of Tanzania meaning \"that which bends up\" or \"stooped walk\" because of the incapacitating arthralgia caused by the disease.",
"   </p>",
"   <p>",
"    Multiple outbreaks beyond West Africa have been described. Since 2004 chikungunya has spread broadly, causing massive outbreaks with explosive onset in the Indian Ocean region, India and other parts of Asia (",
"    <a class=\"graphic graphic_figure graphicRef57430 \" href=\"UTD.htm?31/24/32132\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Chikungunya had traditionally been perceived as a tropical disease until an outbreak in Italy in 2007. In addition, thousands of cases have been identified in travelers returning from outbreak areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/3\">",
"     3",
"    </a>",
"    ]. Because of the wide distribution of mosquito vectors capable of transmitting chikungunya virus, in the future transmission could also occur in regions of the Americas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endemic areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya virus is endemic in parts of West Africa where it appears to be maintained in a cycle involving humans, Aedes mosquitoes, primates and perhaps other animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Serosurveys of humans in parts of West Africa have identified antibodies to chikungunya virus in 35 to 50 percent of the population in the absence of recognized outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spread and resurgence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya virus spreads by means of travel of infected individuals between regions where competent mosquitoes exist for perpetuation of local transmission. Imported cases have been described in many Asian and European countries, as well as in the United States and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. Rapid spread in the last few years may also be related to a viral mutation that enhances replication efficiency in the Aedes albopictus mosquito. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Transmission'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Mutation of virus and vector replication'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After chikungunya virus was identified during an outbreak in East Africa in Tanzania in the early 1950s, the virus was noted to be the cause of multiple outbreaks in many countries of central, southern, and western Africa. Outside Africa, the first documented chikungunya fever outbreak was in Thailand in 1958. This was followed by outbreaks in multiple other Asian countries, including India, Sri Lanka, Malaysia, Indonesia, Cambodia, Vietnam, Myanmar, the Philippines, and Pakistan (",
"    <a class=\"graphic graphic_figure graphicRef57430 \" href=\"UTD.htm?31/24/32132\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After a period of relatively little chikungunya activity, large outbreaks were observed in Africa in the late 1990s. In the Democratic Republic of the Congo, for example, an urban outbreak involved an estimated 50,000 people in 1999-2000. Epidemics also occurred in Indonesia in 2001-2003 after decades without obvious chikungunya fever cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indian Ocean and Asia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid spread of chikungunya virus has been observed in outbreaks involving the Indian Ocean islands, where attack rates have been extremely high in previously unexposed populations (",
"    <a class=\"graphic graphic_figure graphicRef57430 \" href=\"UTD.htm?31/24/32132\">",
"     figure 1",
"    </a>",
"    ). A massive outbreak in Lamu (an island off the coast of Kenya) affected thousands in 2004; a seroprevalence study suggested that the widespread epidemic may have affected 75 percent of the island's 18,000 inhabitants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/14\">",
"     14",
"    </a>",
"    ]. The epidemic on Reunion Island in 2005-2006 involved approximately 266,000 individuals (34 percent of the island's population); a higher attack rate was observed among elderly residents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/15\">",
"     15",
"    </a>",
"    ]. In the Comoro Islands, a seroprevalence study found 63 percent positive for chikungunya virus antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In India, nearly 1.4 million cases of chikungunya fever were reported in 2006, and outbreaks have continued to occur. The appearance and spread of chikungunya virus in India was observed after a hiatus of almost 32 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Chikungunya virus also reappeared in Malaysia in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/19\">",
"     19",
"    </a>",
"    ], in Thailand in 2008, in small outbreaks in Singapore in 2008, and caused an outbreak in Guangdong Province, China in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Europe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although chikungunya fever has traditionally been considered a disease of tropical and subtropical regions, in the summer of 2007 chikungunya virus caused an outbreak in northeastern Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/21\">",
"     21",
"    </a>",
"    ]. The index case was a traveler from India who became ill while visiting Italy, and phylogenetic analysis of the virus demonstrated similarity with chikungunya strains found in the Indian Ocean outbreaks.",
"   </p>",
"   <p>",
"    Between July and September 2007, 205 cases of chikungunya fever were identified in Italy by epidemiologic and clinical criteria; 175 cases were confirmed by laboratory testing. The clinical attack rate in the two affected Italian villages was 5.4 and 2.5 percent but increased with age (1.6 percent for residents &lt;40 years old versus 8.8 percent for those 80 years of age and older) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/21\">",
"     21",
"    </a>",
"    ]. Cases of chikungunya fever related to local transmission ceased in Italy when temperatures dropped, and human cases were not reported in 2008. Local transmission occurred in France in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the Indian Ocean islands, India, and Malaysia are popular tourist destinations among European travelers, many imported cases of chikungunya fever appeared in Europe at the time of the outbreaks in India and the Indian Ocean islands [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In endemic areas of Africa, chikungunya virus transmission occurs in a cycle involving humans, several species of Aedes mosquitoes that inhabit forests and villages, and animals (non-human primates and perhaps other animals). In Asia and elsewhere, however, major outbreaks are sustained by mosquito transmission among susceptible humans. The virus can spread via travel of infected individuals between regions where competent mosquitoes exist for perpetuation of local transmission. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mosquito vectors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major chikungunya virus mosquito vectors are Aedes aegypti and Aedes albopictus. These vectors are also capable of transmitting dengue virus, which, like chikungunya virus, is increasing in geographic range and intensity of transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=see_link\">",
"     \"Mosquito vectors of infectious diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=see_link\">",
"     \"Epidemiology of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Aedes aegypti",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ae. aegypti is well adapted to urban settings and is widely distributed in urban areas of the tropics and subtropics. It prefers the human host as a source of blood meals and breeds readily in flowerpots and in trash, such as discarded cups. A single Ae. aegypti mosquito may be able to infect more than one human, since this species feeds on another host if its blood meal is interrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Aedes albopictus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ae. albopictus (the so-called Asian tiger mosquito) is competent to transmit a number of arboviruses in the laboratory (including yellow fever, West Nile, Japanese encephalitis, and eastern equine encephalitis viruses). It bites a range of animal species so has been considered a relatively inefficient vector, since blood meals taken from nonsusceptible hosts do not contribute to virus transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/24\">",
"     24",
"    </a>",
"    ]. However, some populations of Ae. albopictus may be more anthropophilic (eg, preferring human blood) than others; in some settings humans may be the most abundant host [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ae. albopictus has become widely dispersed beyond Asia; it is now established in many parts of the Americas, Europe, Africa, and the Pacific Islands [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/25\">",
"     25",
"    </a>",
"    ]. Modes of mosquito dissemination include transport of mosquito larvae and eggs in used tires by container ships, and air traffic with subsequent establishment in new areas with suitable environmental and climatic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Outbreaks of chikungunya fever in Italy and Reunion have resulted from virus transmission by Ae. albopictus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Subsequently simultaneous outbreaks of chikungunya fever and dengue infections have been documented in Central Africa (Gabon) in association with the introduction of the Aedes albopictus vector. Dengue-chikungunya co-infections have been documented in humans and in a wild-caught mosquito [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mosquito competence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquito susceptibility to infection by chikungunya virus and mosquito competence for virus transmission can vary [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/29\">",
"     29",
"    </a>",
"    ]. Among Ae. aegypti and Ae. albopictus strains in Florida evaluated for susceptibility to infection by and competence for transmission of a chikungunya virus from the Reunion outbreak, all mosquitoes were susceptible to infection and capable of transmitting the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, local mosquitoes possess the capacity to serve as vectors for transmission of chikungunya virus in Florida.",
"   </p>",
"   <p>",
"    Similarly, Ae. albopictus collected in southern France demonstrated high susceptibility to infection with chikungunya virus (77.1 percent), which was comparable to the susceptibility of mosquitoes collected from Reunion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/31\">",
"     31",
"    </a>",
"    ]. Given the wide distribution of mosquito vectors capable of transmitting chikungunya virus, future transmission could occur in regions of the Americas and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Seasonal synchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order for a viremic traveler to initiate a local outbreak in a non endemic area, there must be seasonal synchrony between the geographic source of ongoing viral transmission and the geographic destination vulnerable to introduction of infection (due to infestation with competent mosquito vectors) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/32\">",
"     32",
"    </a>",
"    ]. For example, transmission of chikungunya virus in Italy during the summer of 2007 was successful because of presence of virus in an individual traveling within the northern hemisphere between India and Italy; the period of active transmission in India coincided with Italy's hottest months. Spread from the southern to northern hemisphere is less likely because the warm seasons and vector activity for these regions may not be synchronous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extrinsic incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extrinsic incubation period is the period between a mosquito blood meal from a viremic host and the transmission of virus to a new host. During this period the virus must replicate and reach the mosquito salivary glands so that it will be transmitted to a new host when the mosquito takes the next blood meal. The extrinsic incubation period varies depending on the virus, the mosquito vector, and environmental conditions including temperature and humidity. In general, the warmer the temperature, the shorter the extrinsic incubation period and the sooner the mosquito can transmit virus to a new host. In cool temperatures and in many temperate areas, a mosquito may die before the extrinsic incubation period is complete.",
"   </p>",
"   <p>",
"    The mutation in the chikungunya virus strain that caused the massive outbreak on Reunion (described below) may also be capable of shortening the extrinsic incubation period, allowing more mosquitoes to survive long enough to transmit virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Mutation of virus and vector replication'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nosocomial and vertical transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional modes of transmission include nosocomial and vertical transmission. Nosocomial transmission has been described in France, where a nurse was infected by exposure to blood while caring for a patient infected in Reunion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Transmission via transfusion of blood products",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organ transplantation could also occur, since chikungunya viremia (may exceed 10(9) RNA",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    plasma) is likely prior to onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/9,34\">",
"     9,34",
"    </a>",
"    ]. Chikungunya virus infects the human cornea and could be transmitted via corneal grafts. Infected corneas have been documented in individuals in the absence of systemic symptoms of chikungunya infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vertical transmission of chikungunya has been described in Reunion; among 39 women in the outbreak with viremia at the time of delivery, the rate of vertical transmission was 48.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/36\">",
"     36",
"    </a>",
"    ]. Symptoms among neonates were observed within three to seven days and included fever, poor feeding, and rash; 89 percent had thrombocytopenia. Among 19 infected neonates, 10 had severe disease, primarily encephalopathy. Caesarean delivery was not protective against vertical transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya is a single-stranded RNA virus of the genus Alphavirus (Togaviridae family). It was first isolated from mosquitoes and humans during an outbreak in Tanganyika (Tanzania) in 1952-53 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus far, three lineages distinguishable by genotypic and antigenic characteristics have been identified: the clusters of",
"    <span class=\"nowrap\">",
"     central/east",
"    </span>",
"    Africa, West Africa, and Asia.",
"   </p>",
"   <p>",
"    Other alphaviruses that cause illnesses associated with fever and arthralgia or arthritis include O'nyong-nyong (east and central Africa), Barmah and Ross River viruses (Australia and the Pacific), Semliki virus (Africa), Mayaro virus (South America), and Sindbis group viruses (widespread excluding the Americas) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/23,38\">",
"     23,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of the severe and persistent joint symptoms that characterize chikungunya virus infections is uncertain. Some data suggest that macrophage-derived products such as tumor necrosis factor-alpha, interferon-gamma, and macrophage chemoattractant protein-1 may play important roles in the joint tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mutation of virus and vector replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The replication efficiency of chikungunya virus within the Ae. albopictus mosquito may be enhanced in the presence of a mutation in the viral gene encoding the envelope protein of the virus (mutation A226V). This mutation was observed in &gt;90 percent of viral sequences in the latter period of the Reunion outbreak, although it was not observed in the initial outbreak strains, suggesting an enhanced survival benefit for this mutant (A226V) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/40\">",
"     40",
"    </a>",
"    ]. The mutation was also found in chikungunya virus isolates from the outbreak in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of this mutation has been associated with enhanced Ae. albopictus susceptibility to infection and more rapid viral dissemination into the mosquito salivary glands [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/33\">",
"     33",
"    </a>",
"    ]. As a result, a lower level of human viremia is required for transmission of this mutant virus to a biting mosquito, facilitating the cycle of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical signs and symptoms begin abruptly with fever and malaise following an incubation period of two to four days (range 1 to 14).",
"   </p>",
"   <p>",
"    Fever may be high grade (40&ordm;C); the usual duration of fever is three to five days (range 1 to 10 days). Polyarthralgia begins two to five days after onset of fever and commonly involves multiple joints (often 10 or more joint groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/7,18,42,43\">",
"     7,18,42,43",
"    </a>",
"    ]. Joints affected include hands (50 to 76 percent), wrists (29 to 81 percent), and ankles (41 to 68 percent). Arthralgia is symmetrical in 64 to 73 percent and involves distal joints more than proximal joints. Involvement of the axial skeleton was noted in 34 to 52 percent of cases. Pain may be intense and disabling, leading to immobilization.",
"   </p>",
"   <p>",
"    Skin manifestations have been reported in 40 to 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/18,43\">",
"     18,43",
"    </a>",
"    ]. The most common skin manifestation is macular or maculopapular rash (usually appearing three days or later after onset of illness and lasting three to seven days). The rash often starts on on the limbs and trunk, can involve the face, and may be patchy or diffuse. Islands of normal skin may be seen along with the diffuse rash. Pruritus has been reported in 25 to 50 percent of patients in some series. Bullous skin lesions have also been described, most often in children. Hemorrhagic manifestations are uncommon.",
"   </p>",
"   <p>",
"    Additional manifestations may include headache, myalgia, and gastrointestinal symptoms.",
"   </p>",
"   <p>",
"    On physical examination periarticular edema or swelling has been observed in 32 to 95 percent of cases. In one series large joint effusions were noted in 15 percent of cases. Peripheral lymphadenopathy (most often cervical) may be present (9 to 41 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/8,44\">",
"     8,44",
"    </a>",
"    ]. Conjunctivitis may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common laboratory abnormalities are lymphopenia and thrombocytopenia. Liver enzymes may be elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following acute illness (usually lasting 7 to 10 days), some patients may experience persistent rheumatologic signs and symptoms including",
"    <span class=\"nowrap\">",
"     arthritis/arthralgia,",
"    </span>",
"    edematous polyarthritis of fingers and toes, morning pain and stiffness and severe tenosynovitis (especially of wrists, hands and ankles) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/46\">",
"     46",
"    </a>",
"    ]. Carpal tunnel syndromes may result from hypertrophic tenosynovitis. In addition, patients may report joint or bone pain at sites of previous injury. Occasionally, unusual joints (such as sternoclavicular or temperomandibular joints) are involved. New onset Raynaud phenomena in the second or third month following infection have been described in up to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/42\">",
"     42",
"    </a>",
"    ]. Cryoglobulinemia has also been found in patients with persistent symptoms attributed to chikungunya infection; &gt;90 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of persistent symptoms is variable. Among 47 patients with acute chikungunya fever followed in Marseilles, France, 82 percent had persistent joint symptoms. At one, three, and six months following acute illness, symptoms persisted in 88, 86, and 48 percent of patients, respectively; at 15 months, 4 percent remained symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/42\">",
"     42",
"    </a>",
"    ]. In contrast, among 88 patients in Reunion evaluated a mean of 18 months after confirmation of acute chikungunya infection, 63 percent reported persistent polyarthralgia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/44\">",
"     44",
"    </a>",
"    ]. Morning stiffness was reported by 75 percent of individuals, and almost half reported that the pain had a negative impact on daily activities. One study in South Africa reported arthralgia 3 years after the acute illness in 12 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Severe complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older reports chikungunya fever has been described as a self-limited illness, although severe complications and death have been reported in the more recent outbreaks. It is unclear whether these differences reflect a modulation in virus virulence, improved epidemiologic observation, or both. Severe complications and death occur more often among patients older than 65 years and in those with underlying chronic medical problems.",
"   </p>",
"   <p>",
"    Severe complications include respiratory failure, cardiovascular decompensation, myocarditis, acute hepatitis, renal failure and neurologic involvement. Meningoencephalitis is the most common neurologic complication; other manifestations include acute flaccid paralysis and Guillain Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Ocular manifestations (iridocyclitis, retinitis, episcleritis, macular choroiditis) and sensorineural hearing loss have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/45,52,53\">",
"     45,52,53",
"    </a>",
"    ]. In Reunion, the estimated incidence of severe disease (eg, hospitalized patients with complications, such as respiratory failure, meningoencephalitis, acute hepatitis, or kidney failure) was 17 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/15,54\">",
"     15,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deaths associated with chikungunya virus infection were reported during outbreaks in Mauritius, Reunion, and India [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. In Reunion there were 228 deaths; the mean age was 78 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/54\">",
"     54",
"    </a>",
"    ]. During the chikungunya epidemic in Ahmedabad, India in 2006, about 60,000 cases were described; the number of deaths during the four months of peak epidemic activity exceeded the average death rate during those months in the previous four years by almost 3000 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Subclinical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals have serologic evidence for exposure to chikungunya virus infection in the absence of clinical symptoms. As noted above, in West Africa seropositivity has been noted in 35 to 50 percent of the individuals in the absence of recognized outbreaks. During the Reunion outbreak, a survey found that about 3.2 percent of military policemen were seropositive in the absence of clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/58\">",
"     58",
"    </a>",
"    ]. A Thai study noted a ratio of clinical-to-subclinical chikungunya infection of about 1.8:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya and dengue virus infections have some common clinical symptoms and areas of geographic distribution; distinguishing them may be difficult in the setting of acute febrile illness with rash. However, polyarthralgia occurs in virtually all cases of chikungunya fever but is not typical of dengue fever (though dengue fever patients commonly have myalgias).",
"   </p>",
"   <p>",
"    Other infections in the differential diagnosis include other viral infections (primary HIV infection, measles, rubella, Ross River virus), malaria, rickettsial infections, relapsing fever, leptospirosis, meningococcal infections, EBV, and enteric fever (typhoid and paratyphoid fevers). In a study of 62 returned travelers with fever and rash seen in Paris between January 2006 and September 2007, the most common diagnoses were chikungunya (35 percent), dengue (26 percent), and African tick bite fever (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/60\">",
"     60",
"    </a>",
"    ]. Leukopenia, neutropenia and thrombocytopenia were significantly more common in patients diagnosed with dengue than chikungunya.",
"   </p>",
"   <p>",
"    If the clinical course is atypical or fever persists longer than five to seven days, the possibility of dual infection should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/61\">",
"     61",
"    </a>",
"    ]. Chikungunya virus outbreaks have occurred simultaneously with outbreaks of dengue or yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/62\">",
"     62",
"    </a>",
"    ], and coinfection with chikungunya virus and other pathogens has been described (eg, chikungunya and dengue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/63\">",
"     63",
"    </a>",
"    ], chikungunya and yellow fever [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/61\">",
"     61",
"    </a>",
"    ], chikungunya and amebiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/64\">",
"     64",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic techniques for identification of chikungunya virus include serology, viral culture and molecular techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/9,18,38\">",
"     9,18,38",
"    </a>",
"    ]. Serology is the primary tool for diagnosis in the clinical setting. IgM anti-chikungunya virus antibodies (detected by direct enzyme-linked immunosorbent assay [ELISA]) are present starting about five days (range 1 to 12 days) following onset of symptoms and persist for several weeks to three months. IgG antibodies begin to appear about two weeks following onset of symptoms and persist for years.",
"   </p>",
"   <p>",
"    In endemic areas chikungunya infection can be suspected based on characteristic clinical findings in outbreaks; in endemic areas where good laboratory facilities are unavailable, many infections may remain undiagnosed.",
"   </p>",
"   <p>",
"    Viral culture and molecular techniques are important research tools. Chikungunya virus can be isolated from blood during the first week of illness using mosquito cells, mammalian cells (Vero), or in mice. Sensitivity of viral culture is high in early infection but drops five days after onset of illness. Chikungunya virus RNA can also be detected by RT-PCR during the first five days following onset of symptoms with excellent sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/9\">",
"     9",
"    </a>",
"    ]. Virus isolation allows identification of the viral strain and can be important for epidemiologic and research purposes, but RT-PCR is faster than culture with greater sensitivity and specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of chikungunya infection consists of supportive care including anti-inflammatory agents that relieve symptoms in many patients and analgesic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/42\">",
"     42",
"    </a>",
"    ]. No antiviral agents have been shown to be effective in human infection, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and interferon-alpha appear to have in vitro activity against virus replication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/65\">",
"     65",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    sulfate has been suggested as a possible treatment because of its anti-inflammatory properties, but has not been demonstrated to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/66\">",
"     66",
"    </a>",
"    ]. For seriously ill patients, there are insufficient data for use of corticosteroids or antiviral therapy. The documentation of long-term viral persistence in non-human primates raises questions about the roles immune dysregulation and persistent virus in chronic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No vaccine is available for prevention of chikungunya infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/68\">",
"     68",
"    </a>",
"    ]. Prevention consists of minimizing mosquito exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15576/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients receiving care in an area inhabited by mosquitoes competent to transmit chikungunya virus should be treated in screened, mosquito-free areas or under a bednet to avoid spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chikungunya is an arthropod-borne virus (arbovirus) endemic to West Africa that causes acute febrile polyarthralgia and arthritis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chikungunya virus appears to spread across wide geographic areas via travel of infected individuals between regions where competent mosquitoes exist for perpetuation of local transmission. Multiple outbreaks beyond West Africa have been described; since 2004 chikungunya virus has spread broadly, causing massive outbreaks with explosive onset in the Indian Ocean region, India, other parts of Asia, and Europe. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of acute infection include high fever and bilateral polyarthralgia with intense pain. The most common skin manifestation is macular or maculopapular rash (usually appearing three days or later after onset of illness and lasting three to seven days). Additional manifestations may include headache, myalgia, and gastrointestinal symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients experience persistent rheumatologic symptoms following acute illness. These may include polyarthralgia, morning stiffness, tenosynovitis and Raynaud phenomena. Severe complications (including meningoencephalitis, cardiopulmonary decompensation, acute renal failure and death) have been described with greater frequency among patients older than 65 years and those with underlying chronic medical problems. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Persistent symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Severe complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serology is the primary tool for diagnosis in the clinical setting. IgM anti-chikungunya virus antibodies are present starting about five days (range 1 to 12 days) following onset of symptoms and persist for several weeks to three months. IgG antibodies start to appear about two weeks following onset of symptoms and persist for years. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of chikungunya infection consists of supportive care including anti-inflammatory and analgesic agents. No antiviral agents have been shown to be effective in human infection. Prevention consists of minimizing mosquito exposure. Patients receiving care in an area inhabited by mosquitoes competent to transmit chikungunya should be treated in screened, mosquito-free areas or under a bednet to avoid spread. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/1\">",
"      Charrel RN, de Lamballerie X, Raoult D. Chikungunya outbreaks--the globalization of vectorborne diseases. N Engl J Med 2007; 356:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/2\">",
"      Mavalankar D, Shastri P, Raman P. Chikungunya epidemic in India: a major public-health disaster. Lancet Infect Dis 2007; 7:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/3\">",
"      Enserink M. Infectious diseases. Chikungunya: no longer a third world disease. Science 2007; 318:1860.",
"     </a>",
"    </li>",
"    <li>",
"     Pan American Health Organization. Preparedness and response for chikungunya virus: introduction into the Americas. Washington, DC: PAHO; 2011. file://new.paho.org/hq/index.php?option=com_content&amp;task=view&amp;id=6464&amp;itemid=1926 (Accessed on October 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/5\">",
"      Chevillon C, Briant L, Renaud F, Devaux C. The Chikungunya threat: an ecological and evolutionary perspective. Trends Microbiol 2008; 16:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/6\">",
"      Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 2009; 49:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/7\">",
"      Parola P, de Lamballerie X, Jourdan J, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006; 12:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/8\">",
"      Hochedez P, Jaureguiberry S, Debruyne M, et al. Chikungunya infection in travelers. Emerg Infect Dis 2006; 12:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/9\">",
"      Panning M, Grywna K, van Esbroeck M, et al. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis 2008; 14:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/10\">",
"      Lanciotti RS, Kosoy OL, Laven JJ, et al. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis 2007; 13:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/11\">",
"      Nicoletti L, Ciccozzi M, Marchi A, et al. Chikungunya and dengue viruses in travelers. Emerg Infect Dis 2008; 14:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Chikungunya fever diagnosed among international travelers--United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2006; 55:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Update: chikungunya fever diagnosed among international travelers--United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/14\">",
"      Sergon K, Njuguna C, Kalani R, et al. Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg 2008; 78:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/15\">",
"      Renault P, Solet JL, Sissoko D, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007; 77:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/16\">",
"      Sissoko D, Malvy D, Giry C, et al. Outbreak of Chikungunya fever in Mayotte, Comoros archipelago, 2005-2006. Trans R Soc Trop Med Hyg 2008; 102:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/17\">",
"      Yergolkar PN, Tandale BV, Arankalle VA, et al. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 2006; 12:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/18\">",
"      Lakshmi V, Neeraja M, Subbalaxmi MV, et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. Clin Infect Dis 2008; 46:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/19\">",
"      AbuBakar S, Sam IC, Wong PF, et al. Reemergence of endemic Chikungunya, Malaysia. Emerg Infect Dis 2007; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/20\">",
"      Wu D, Wu J, Zhang Q, et al. Chikungunya outbreak in Guangdong Province, China, 2010. Emerg Infect Dis 2012; 18:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/21\">",
"      Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007; 370:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/22\">",
"      Gould EA, Gallian P, De Lamballerie X, Charrel RN. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect 2010; 16:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/23\">",
"      Pialoux G, Ga&uuml;z&egrave;re BA, Jaur&eacute;guiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007; 7:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/24\">",
"      Reiter P, Fontenille D, Paupy C. Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem? Lancet Infect Dis 2006; 6:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/25\">",
"      Enserink M. Entomology. A mosquito goes global. Science 2008; 320:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/26\">",
"      Gubler DJ. Aedes albopictus in Africa. Lancet Infect Dis 2003; 3:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/27\">",
"      Tatem AJ, Hay SI, Rogers DJ. Global traffic and disease vector dispersal. Proc Natl Acad Sci U S A 2006; 103:6242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/28\">",
"      Caron M, Paupy C, Grard G, et al. Recent introduction and rapid dissemination of Chikungunya virus and Dengue virus serotype 2 associated with human and mosquito coinfections in Gabon, central Africa. Clin Infect Dis 2012; 55:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/29\">",
"      Tesh RB, Gubler DJ, Rosen L. Variation among goegraphic strains of Aedes albopictus in susceptibility to infection with chikungunya virus. Am J Trop Med Hyg 1976; 25:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/30\">",
"      Reiskind MH, Pesko K, Westbrook CJ, Mores CN. Susceptibility of Florida mosquitoes to infection with chikungunya virus. Am J Trop Med Hyg 2008; 78:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/31\">",
"      Vazeille M, Jeannin C, Martin E, et al. Chikungunya: a risk for Mediterranean countries? Acta Trop 2008; 105:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/32\">",
"      Charrel RN, de Lamballerie X, Raoult D. Seasonality of mosquitoes and chikungunya in Italy. Lancet Infect Dis 2008; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/33\">",
"      Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3:e201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/34\">",
"      Brouard C, Bernillon P, Quatresous I, et al. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008; 48:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/35\">",
"      Couderc T, Gangneux N, Chr&eacute;tien F, et al. Chikungunya virus infection of corneal grafts. J Infect Dis 2012; 206:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/36\">",
"      G&eacute;rardin P, Barau G, Michault A, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La R&eacute;union. PLoS Med 2008; 5:e60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/37\">",
"      LUMSDEN WH. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology. Trans R Soc Trop Med Hyg 1955; 49:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/38\">",
"      Simon F, Savini H, Parola P. Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am 2008; 92:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/39\">",
"      Lidbury BA, Rulli NE, Suhrbier A, et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis 2008; 197:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/40\">",
"      Schuffenecker I, Iteman I, Michault A, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 2006; 3:e263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/41\">",
"      Bordi L, Carletti F, Castilletti C, et al. Presence of the A226V mutation in autochthonous and imported Italian chikungunya virus strains. Clin Infect Dis 2008; 47:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/42\">",
"      Simon F, Parola P, Grandadam M, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore) 2007; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/43\">",
"      Taubitz W, Cramer JP, Kapaun A, et al. Chikungunya fever in travelers: clinical presentation and course. Clin Infect Dis 2007; 45:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/44\">",
"      Borgherini G, Poubeau P, Staikowsky F, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis 2007; 44:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/45\">",
"      Mahendradas P, Ranganna SK, Shetty R, et al. Ocular manifestations associated with chikungunya. Ophthalmology 2008; 115:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/46\">",
"      Parola P, Simon F, Oliver M. Tenosynovitis and vascular disorders associated with Chikungunya virus-related rheumatism. Clin Infect Dis 2007; 45:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/47\">",
"      Oliver M, Grandadam M, Marimoutou C, et al. Persisting mixed cryoglobulinemia in Chikungunya infection. PLoS Negl Trop Dis 2009; 3:e374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/48\">",
"      Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection. A retrospective study of 107 cases. S Afr Med J 1983; 63:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/49\">",
"      Robin S, Ramful D, Le Seach' F, et al. Neurologic manifestations of pediatric chikungunya infection. J Child Neurol 2008; 23:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/50\">",
"      Singh SS, Manimunda SP, Sugunan AP, et al. Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect 2008; 136:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/51\">",
"      Wielanek AC, Monredon JD, Amrani ME, et al. Guillain-Barr&eacute; syndrome complicating a Chikungunya virus infection. Neurology 2007; 69:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/52\">",
"      Chanana B, Azad RV, Nair S. Bilateral macular choroiditis following Chikungunya virus infection. Eye (Lond) 2007; 21:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/53\">",
"      Bhavana K, Tyagi I, Kapila RK. Chikungunya virus induced sudden sensorineural hearing loss. Int J Pediatr Otorhinolaryngol 2008; 72:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/54\">",
"      Paquet C, Quatresous I, Solet JL, et al. Chikungunya outbreak in Reunion: epidemiology and surveillance, 2005 to early January 2006. Euro Surveill 2006; 11:E060202.3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/55\">",
"      Beesoon S, Funkhouser E, Kotea N, et al. Chikungunya fever, Mauritius, 2006. Emerg Infect Dis 2008; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/56\">",
"      Josseran L, Paquet C, Zehgnoun A, et al. Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 2006; 12:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/57\">",
"      Mavalankar D, Shastri P, Bandyopadhyay T, et al. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis 2008; 14:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/58\">",
"      Queyriaux B, Simon F, Grandadam M, et al. Clinical burden of chikungunya virus infection. Lancet Infect Dis 2008; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/59\">",
"      Watanaveeradej V, Endy TP, Simasathien S, et al. The study transplacental chikungunya virus antibody kinetics, Thailand. Emerg Infect Dis 2006; 12:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/60\">",
"      Hochedez P, Canestri A, Guihot A, et al. Management of travelers with fever and exanthema, notably dengue and chikungunya infections. Am J Trop Med Hyg 2008; 78:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/61\">",
"      Gould LH, Osman MS, Farnon EC, et al. An outbreak of yellow fever with concurrent chikungunya virus transmission in South Kordofan, Sudan, 2005. Trans R Soc Trop Med Hyg 2008; 102:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/62\">",
"      Ratsitorahina M, Harisoa J, Ratovonjato J, et al. Outbreak of dengue and Chikungunya fevers, Toamasina, Madagascar, 2006. Emerg Infect Dis 2008; 14:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/63\">",
"      Nayar SK, Noridah O, Paranthaman V, et al. Co-infection of dengue virus and chikungunya virus in two patients with acute febrile illness. Med J Malaysia 2007; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/64\">",
"      Ezzedine K, Cazanave C, Pistone T, et al. Dual infection by chikungunya virus and other imported infectious agent in a traveller returning from India. Travel Med Infect Dis 2008; 6:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/65\">",
"      Briolant S, Garin D, Scaramozzino N, et al. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/66\">",
"      Savarino A, Cauda R, Cassone A. On the use of chloroquine for chikungunya. Lancet Infect Dis 2007; 7:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/67\">",
"      Labadie K, Larcher T, Joubert C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15576/abstract/68\">",
"      Edelman R, Tacket CO, Wasserman SS, et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000; 62:681.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Health Information for Interanational Travel, 2009. US Department of Health and Human Services, Public Health Service, Atlanta, GA 2007.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3024 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15576=[""].join("\n");
var outline_f15_13_15576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endemic areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spread and resurgence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indian Ocean and Asia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Europe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mosquito vectors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Aedes aegypti",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Aedes albopictus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mosquito competence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Seasonal synchrony",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extrinsic incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nosocomial and vertical transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mutation of virus and vector replication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Severe complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Subclinical infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3024|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/24/32132\" title=\"figure 1\">",
"      Chikungunya incidence map",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=related_link\">",
"      Epidemiology of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23011?source=related_link\">",
"      Mosquito vectors of infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_13_15577="Identification and management of alcohol use disorders in the perioperative period";
var content_f15_13_15577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Identification and management of alcohol use disorders in the perioperative period",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Adam J Gordon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15577/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/13/15577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use disorders (AUDs) are prevalent in hospitalized patients. AUD, as discussed here, includes patients with a formal diagnosis of alcohol abuse or alcohol dependence, as well as patients with hazardous alcohol consumption (eg, alcohol intake that places patients at risk for alcohol-related harm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identifying AUDs in surgical patients and providing subsequent perioperative care often challenges medical consultants, anesthesiologists, and surgeons. AUDs can lead to significant psychiatric and medical comorbidities that may influence perioperative risk. Because of this, patients with AUDs require special care during the perioperative period.",
"   </p>",
"   <p>",
"    Despite the potential harm associated with failure to identify AUD in the perioperative period, many surgical patients have not had appropriate assessment for alcohol use in the preoperative evaluation. One study found that anesthesiologists identified AUD in 7 percent of preoperative patients, compared to 18 percent identified by a computerized screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, identification, and management of AUDs seen in surgical populations. Diagnosis and management of AUDs in primary care patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use disorders (AUDs) are common in the United States. Lifetime prevalence of alcohol abuse ranges from 14 to 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with AUDs commonly are admitted to surgical and trauma services. In one study of patients admitted to an academic trauma center, 43 percent of the patients who had alcohol levels checked had detectable levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of AUDs in surgical settings is higher than in the general population; a study of inpatients found that 23 percent of general surgery admissions and 43 percent of otolaryngology admissions met criteria for alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALCOHOL USE DISORDERS SEEN IN SURGICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and treatment of patients with alcohol use disorders (AUDs) in the perioperative period is aided by defining the spectrum of AUDs encountered. In general, two broad categories of AUD are important for the practitioner to distinguish: \"at risk\" and \"abuse and dependent\" drinking.",
"   </p>",
"   <p>",
"    At-risk drinkers and people with alcohol abuse or dependence have different levels of alcohol consumption and a different prognosis. At-risk drinkers may have medical consequences of their alcohol consumption that increase risks during the perioperative period. Patients with abuse and dependence are additionally at risk for alcohol withdrawal syndrome (AWS) if they reduce or eliminate alcohol consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     At-risk drinking",
"    </span>",
"    &nbsp;&mdash;&nbsp;People who consume hazardous or harmful levels of alcohol but do not meet criteria for alcohol abuse or dependence are considered to be heavy or \"at-risk\" drinkers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/5\">",
"     5",
"    </a>",
"    ]. Binge drinkers may also be a subset of AUD patients that are at risk for alcohol-related harm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/6-13\">",
"     6-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At-risk drinking is defined by different authorities as a certain quantity and frequency of standard drinks of alcohol consumption. One criterion considers the consumption of greater than 16 standard drinks per week in men or 10 standard drinks per week in women to be \"hazardous drinking\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/14\">",
"     14",
"    </a>",
"    ]. In the United States, the current standard for &ldquo;at risk&rdquo; alcohol consumption is greater than 14 standard drinks (14 grams of pure alcohol) for a man and 7 standard drinks for a woman or man over the age of 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization defines \"harmful drinking\" as the level of alcohol consumption that results in physical or psychological harm, but where the patient does not meet criteria for alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical threshold for current binge drinking is greater than or equal to five alcohol drinks on one occasion for men or four for women in the last year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/8,14,17\">",
"     8,14,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alcohol abuse and dependence",
"    </span>",
"    &nbsp;&mdash;&nbsp;While at-risk drinking is variously defined, the DSM-IV defines alcohol abuse as a maladaptive pattern of use associated with one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to fulfill work, school, or social obligations",
"     </li>",
"     <li>",
"      Recurrent substance use in physically hazardous situations",
"     </li>",
"     <li>",
"      Recurrent legal problems related to substance use",
"     </li>",
"     <li>",
"      Continued use despite alcohol-related social or interpersonal problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alcohol dependence is defined as a maladaptive pattern of use associated with three or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tolerance",
"     </li>",
"     <li>",
"      Withdrawal",
"     </li>",
"     <li>",
"      Substance taken in larger quantity than intended",
"     </li>",
"     <li>",
"      Persistent desire to cut down or control use",
"     </li>",
"     <li>",
"      Time is spent obtaining, using, or recovering from the substance",
"     </li>",
"     <li>",
"      Social, occupational, or recreational tasks are sacrificed",
"     </li>",
"     <li>",
"      Use continues despite physical and psychological problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persons with alcohol abuse and dependence can have significant withdrawal complications in the perioperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alcohol withdrawal syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol withdrawal syndrome (AWS) is a clinical diagnosis that is defined by a constellation of signs and symptoms including autonomic hyperactivity and impaired social and occupational functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .) The time course for the development of AWS is extremely variable. Early symptoms of AWS can begin as early as two hours after cessation or significant reduction of alcohol consumption. Severe AWS symptoms typically peak within four days after onset and usually subside within a week (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signs and symptoms of AWS exist along a spectrum from mild, moderate, to severe. Most patients who experience AWS have mild to moderate symptoms without need for pharmacological treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, patients who experience severe AWS may have significant complications that require intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abstinence from drinking as imposed by a hospital admission places patients with abuse or dependence at risk for AWS. The stress of surgery additionally predisposes patients to or may exacerbate existing AWS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared with all other hospitalized patients, the incidence of AWS is two to five times higher in surgical and trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. While all patients with AUDs are at increased risk for perioperative complications, the development of AWS in alcohol dependent patients constitutes an independent cause of increased morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of AWS may be delayed in the perioperative period, which may contribute to increased morbidity. In a study of 539 episodes of AWS, 21 percent of patients had adverse outcomes such as increased length of stay, delirium, or seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/23\">",
"     23",
"    </a>",
"    ]. Complications correlated with patient age over 70 years, history of seizures, or a delay in initial patient assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4648878\">",
"    <span class=\"h2\">",
"     Impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that alcohol use and misuse contribute to surgical and post-operative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ]. The effects of alcohol on perioperative complications appear to be dose-dependent, with greater consumption incurring a higher rate and severity of peri-operative consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a study of 309,265 hospitalizations for elective surgery found that 2.5 percent of patients had documented, active alcohol use (at least two drinks per day within 2 weeks of surgery). In an analysis adjusted for demographic and comorbid factors, patients using alcohol were more likely than non-users to experience pneumonia, sepsis, wound disruption, and prolonged length of stay. The clinical complications were independent risk factors for postoperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation of patients with potential alcohol use disorders (AUDs) should:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Include effective screening strategies to identify the presence of an AUD",
"     </li>",
"     <li>",
"      Detect end-organ damage secondary to alcohol consumption",
"     </li>",
"     <li>",
"      Prompt intervention on the AUD prior to surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to manage patients with AUDs in the perioperative period it is essential to identify patients with AUDs efficiently and effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/14,27-33\">",
"     14,27-33",
"    </a>",
"    ]. The most effective means to screen for AUDs is through short, validated screening instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying patient characteristics that are often associated with AUDs may assist in effective screening for AUDs. These patient characteristics include the presence of historical factors, comorbid medical or psychiatric conditions, physical examination findings, and laboratory characteristics. Because perioperative patients are often unable to communicate or answer questions on AUD screening instruments, assessment may only be possible through physical and laboratory findings, and laboratory findings can add to the sensitivity of detection when combined with history and screening instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREOPERATIVE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative diagnosis of alcohol use disorders (AUDs) allows the opportunity to anticipate operative and postoperative complications and offer preoperative interventions to reduce perioperative morbidity. Preoperative interventions for patients with AUDs but without alcohol dependence can include abstinence and referral for substance abuse counseling. Alcohol dependent patients at risk for alcohol withdrawal syndrome (AWS) may undergo preoperative detoxification and rehabilitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AWS prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AUDs should receive daily multivitamins and high dose thiamine (100 mg) and should also receive oral or parenteral thiamine (100 mg daily) during the preoperative and perioperative periods to prevent stress-induced Wernicke-Korsakoff syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abstinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, abstinence prior to surgery likely offers the best method of reducing or eliminating perioperative complications secondary to AUDs for patients not felt to be at risk for AWS. A meta-analysis of two randomized trials of 69 patients found that a preoperative alcohol cessation intervention led to a reduction in overall postoperative complication rates (odds ratio [OR] 0.22; 95% CI 0.08 to 0.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/35\">",
"     35",
"    </a>",
"    ]. There was no significant reduction of in-hospital or 30-day mortality. As an example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial in 42 patients undergoing colorectal surgery who consumed at least 60g of",
"      <span class=\"nowrap\">",
"       ethanol/day",
"      </span>",
"      compared patients with one month of abstinence controlled with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      prior to surgery to patients who continued to drink [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/36\">",
"       36",
"      </a>",
"      ]. Those patients assigned to the abstinence group experienced significantly fewer postoperative complications such as myocardial ischemia, arrhythmias, infections, and hypoxemic episodes. The response to surgical stress was decreased, and delayed-type hypersensitivity responses were stronger in the abstainers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies of preoperative abstinence are necessary to determine the duration of abstinence needed before surgery to minimize perioperative complications.",
"   </p>",
"   <p>",
"    There is emerging research that brief interventions may prevent alcohol related harm prior to surgical interventions for those patients with at least hazardous alcohol consumption. Brief interventions are time limited discussions where practitioners collaboratively work with the patient to reduce alcohol consumption. One recent study examined a tailored intervention for excessive alcohol consumption prior to elective surgery with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preoperative detoxification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for developing AWS could potentially undergo medical detoxification prior to operative interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .) The decision to enter detoxification treatment requires a motivated patient, and the preoperative evaluation provides an excellent opportunity to educate patients about the consequences of at-risk alcohol use during the perioperative period. The urgency of surgery and patient attitudes about their alcohol use determine the feasibility of preoperative detoxification.",
"   </p>",
"   <p>",
"    Rehabilitation, although not necessarily required as a prerequisite for surgery, should be encouraged to maintain long-term abstinence. Therefore, initiating detoxification during the perioperative period and transitioning to rehabilitation postoperatively is another strategy for patients to consider.",
"   </p>",
"   <p>",
"    Preoperative detoxification will likely reduce the risk of developing AWS during the perioperative period and may also reduce operative morbidity or mortality secondary to AUDs. However, there have been no studies that have evaluated the effect of preoperative alcohol detoxification on surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alcohol withdrawal syndrome prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with AUDs identified preoperatively remain at risk for developing AWS during the perioperative period. These patients include those with a past history of AWS, alcohol dependent patients who have refused preoperative detoxification or who require urgent surgery that does not permit time for detoxification, patients with ongoing hazardous drinking, and patients who present intoxicated.",
"   </p>",
"   <p>",
"    For patients at risk for AWS, prevention of the development of AWS can be achieved by administration of AWS prophylaxis. Providing early and adequate prophylaxis for AWS appears to reduce postoperative complications and shorten length of ICU stay compared with alcohol dependent patients not receiving prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little published evidence on how to best identify which patients are at sufficient risk for AWS to warrant the administration of prophylaxis. Withdrawal is one criterion for establishing a diagnosis of alcohol dependence (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Alcohol abuse and dependence'",
"    </a>",
"    above), and so patients who meet criteria for alcohol dependence have the greatest risk of perioperative AWS and should clearly receive prophylaxis. With other patients, particularly where the extent of alcohol consumption is not clear because of perioperative issues such as intubation, sedation, or pain, we favor administering prophylaxis to any patient where there is a suspicion of an AUD. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Alcohol abuse and dependence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Initiation of AWS prophylaxis should begin upon cessation of alcohol consumption or admission to the hospital. Delaying the initiation of AWS prophylaxis until the postoperative period places the patient at risk for developing AWS during surgery, when perioperative stress is at its peak.",
"   </p>",
"   <p>",
"    AWS prophylaxis is accomplished by treating patients at risk for AWS with cross-tolerant medications during the immediate perioperative period. Evidence from a large meta-analysis and a review of AWS treatment strategies supports the use of benzodiazepines as first line treatment for AWS prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Suggested prophylactic regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2.5 to 10 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 2 mg, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    5 to 25 mg every 6 hours during the time of potential AWS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of AWS prophylaxis does not prohibit future detoxification and rehabilitation. The multiple contacts with providers that occur during the perioperative period can be used to encourage patients to seek treatment for their AUDs. The need for surgery itself can be a powerful motivator for modifying behaviors that may have contributed to health problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Referral to addiction specialist prior to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to consult an addiction specialist or psychiatrist experienced in evaluation and treatment of AUDs depends upon the treating physician's level of comfort with AUDs. Involvement prior to surgery, if possible, is extremely important as the consultant can interview the patient, identify the presence of AUD, determine risk of AWS, and develop a plan with the patient to minimize surgical morbidity secondary to AUD. Although such referral is likely beneficial for many patients, we know of no studies that have evaluated the impact of expert consultation on AUD treatment outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During surgery, patients with alcohol use disorders (AUDs) require special attention. Provider awareness of a patient's AUD allows for anticipation of increased anesthetic and analgesia requirements and heightened responses to surgical stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Response to anesthesia and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;AUDs among surgical patients can complicate the administration and dosing of anesthesia and analgesia. Due to the widespread and complex effects of alcohol on virtually all organ systems, it is important to recognize and modify dosages and intervals of administration of intraoperative medications in patients with AUDs.",
"   </p>",
"   <p>",
"    Acute alcohol consumption prior to surgery may prolong the duration of action of several medications used during surgery including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/41\">",
"     41",
"    </a>",
"    ]. Chronic alcohol consumption induces the cytochrome P-450 system, potentially shortening the duration of action of medications used during surgery.",
"   </p>",
"   <p>",
"    Several studies have documented increased anesthesia requirements among patients with AUDs for both induction and analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients consuming greater than 40g",
"      <span class=\"nowrap\">",
"       alcohol/day",
"      </span>",
"      for at least two years require more",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      to induce anesthesia than is needed for social drinkers (&lt;40g",
"      <span class=\"nowrap\">",
"       alcohol/day)",
"      </span>",
"      or nondrinkers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcoholics require significantly larger doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      than nondrinkers to achieve adequate analgesia at the time of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased anesthesia and analgesia requirements seen among patients with AUDs are thought to be due to cross-tolerance. Among the AUDs, only alcohol dependence includes tolerance as a diagnostic criterion; however, any patient with a history of regular alcohol consumption may require additional anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute physical stress activates the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased serum cortisol levels. Surgery is a known potent stimulus for HPA activation. The \"surgical stress\" response triggers multiple physiologic changes including increased heart rate, elevated blood pressure, and increased plasma catecholamine levels. The stress response begins at the time of incision, peaks upon cessation of anesthesia and return of pain sensation, and continues throughout the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Understanding of the influence of AUDs on the surgical stress response is limited, but studies suggest a positive correlation. Patients with AUDs exhibit increased responses to surgical stress compared with normal controls as measured by increased plasma catecholamines and cortisol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/24,46\">",
"     24,46",
"    </a>",
"    ]. The irregular stress response in patients with AUDs may contribute to increased morbidity postoperatively through immunosuppression and increased cardiovascular demand [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/36\">",
"     36",
"    </a>",
"    ]. Due to similarities in pathophysiology, alcohol withdrawal syndrome (AWS) and stress responses can have additive effects. Patients with AWS have increased levels of norepinephrine compared with controls following surgery. The severity of withdrawal symptoms correlates with norepinephrine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, similarities in the presentations of AWS and stress responses can delay time to recognition of AWS in alcohol dependent patients, increasing morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other intraoperative considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the altered medication requirements and heightened stress responses, the operative team must pay close attention to avoid intraoperative complications that can affect postoperative outcomes of AUD patients. Close attention to adequate hemostasis may prevent the development of complications. A study of patients with traumatic hemorrhage found patients with AUDs less able to maintain adequate blood pressures during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/46\">",
"     46",
"    </a>",
"    ]. Intraoperative episodes of hypoxemia or hypotension increase the risk of postoperative delirium in patients with AUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS AND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with alcohol use disorders (AUDs) require close attention during the postoperative period to detect alcohol withdrawal syndrome (AWS) and minimize complications. Studies that have compared patients with AUDs to normal controls or social drinkers have found increased postoperative morbidity and mortality among patients with AUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/24,38,49-57\">",
"     24,38,49-57",
"    </a>",
"    ]. A review of studies on postoperative complications found the most common complications experienced by patients with AUDs to be infections, bleeding, and cardiopulmonary insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with AUDs have prolonged intensive care unit (ICU) stays and prolonged overall hospital stays.",
"   </p>",
"   <p>",
"    Arrhythmias can develop in patients with AUDs without preexisting cardiac disease. The \"holiday heart syndrome,\" refers to arrhythmias classically occurring after episodes of binge drinking. Significantly higher bleeding times and an increased frequency of bleeding episodes requiring transfusion have been observed postoperatively in patients with AUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/24,49\">",
"     24,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol abuse is a significant independent risk factor for surgical site infections. Decreased protein accumulation and slower surgical wound healing among patients with alcohol abuse has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several pathogenic mechanisms for increased complications in patients with AUDs have been proposed including immune incompetence, cardiac disease, hemostatic imbalance, and impaired wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/25\">",
"     25",
"    </a>",
"    ]. Chronic alcohol use decreases T-cell activity and proliferation, and delayed type-hypersensitivity (DTH) reactions are decreased pre and postoperatively in patients with AUDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/24\">",
"     24",
"    </a>",
"    ]. Chronic alcohol abuse is a known cause of cardiomyopathy, and patients with AUDs have decreased preoperative ejection fractions compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/36\">",
"     36",
"    </a>",
"    ]. Depressed cardiac function may predispose patients to increased postoperative ischemia and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/24,36\">",
"     24,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link\">",
"     \"Alcoholic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More careful monitoring of patients with AUDs for signs of infection, cerebral complications, and cardiovascular episodes is probably appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alcohol withdrawal syndrome treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosing AWS and establishing the severity of symptoms in the postoperative period is difficult. Postoperative delirium is a common condition, and similarities in presentation between other causes of delirium and AWS may delay time to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/60\">",
"     60",
"    </a>",
"    ]. To adequately diagnose postoperative AWS, other common causes of postoperative delirium must be considered (",
"    <a class=\"graphic graphic_table graphicRef59943 \" href=\"UTD.htm?21/32/22029\">",
"     table 2",
"    </a>",
"    ). Agitation commonly seen in AWS may be falsely attributed to postoperative pain, use of restraints, medications, or continued pulmonary intubation. The use of a preoperative screening assessment of the level of alcohol consumption, the time from last drink to delirium, and the use (or lack of use) of preoperative and operative AWS prophylaxis may also assist in attributing agitation to AWS.",
"   </p>",
"   <p>",
"    Treatment of AWS is guided by the severity of AWS signs and symptoms. An objective validated measure of AWS, the Clinical Institute Withdrawal Assessment Scale for Alcohol-Revised (CIWA-Ar), has been used to measure AWS severity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/61\">",
"     61",
"    </a>",
"    ]. Use of the CIWA-Ar along with symptom-triggered benzodiazepine dosing has been useful in reducing length of stay and amount of benzodiazepines administered to patients undergoing medical detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/62\">",
"     62",
"    </a>",
"    ]. However, administration of CIWA-Ar in the postoperative period may be complicated by endotracheal intubation, decreased level of consciousness, or inability to communicate with the assessor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A survey of United States teaching hospitals found greater than 50 percent of responding institutions had used oral or intravenous ethanol (IVE) to prevent or treat AWS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/64\">",
"     64",
"    </a>",
"    ]. The use of ethanol replacement therapies for AWS remains controversial, and limited data are available to support this practice. There have been conflicting results in studies of IVE for AWS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15577/abstract/3,65-70\">",
"     3,65-70",
"    </a>",
"    ], and further well-controlled trials are needed before IVE can be recommended, given the good evidence for benefit with other therapies such as benzodiazepines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the existing work on detecting and treating &ldquo;at risk&rdquo; alcohol consumption and alcohol use disorders (AUDs) has been conducted in non-surgical settings. As such, many of the following recommendations are based upon extrapolations from such evidence or expert opinions. Further research is required to verify the applicability of many of these approaches to patients who are being identified or managed in the perioperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Preoperative recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conduct an assessment for alcohol use, at-risk use, and alcohol use disorders, with quantity and frequency, followed by a screening questionnaire as part of the preoperative examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"       \"Screening for unhealthy use of alcohol and other drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients unable to complete AUD screening questionnaires, consider laboratory studies and surrogate interviews to assess for AUDs.",
"     </li>",
"     <li>",
"      If the screen is positive for an AUD, assess for evidence of complications of AUDs, such as hepatic injury or bone marrow suppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link\">",
"       \"Alcohol abuse and hematologic disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with AUD who are undergoing non-emergent surgery and who are not alcohol dependent, recommend a period of preoperative abstinence, or reduction of alcohol consumption, and provide education about preoperative and postoperative AUD treatment options.",
"     </li>",
"     <li>",
"      Alcohol dependent patients should consider preoperative detoxification as a strategy to reduce operative risk.",
"     </li>",
"     <li>",
"      Patients with AUDs should receive daily multivitamins and high dose thiamine (100 mg) and should also receive oral or parenteral thiamine (100 mg daily) during the preoperative and perioperative periods.",
"     </li>",
"     <li>",
"      Patients with alcohol dependence who are unwilling or unable to undergo medical detoxification before surgery should receive alcohol withdrawal syndrome (AWS) prophylaxis with benzodiazepines. Prophylaxis should be strongly considered in any patient in whom there is a suspicion of an AUD, particularly if perioperative issues interfere with a complete assessment of alcohol consumption.",
"     </li>",
"     <li>",
"      Suggested prophylactic regimens include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      2.5 to 10 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.5 to 2 mg, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"       chlordiazepoxide",
"      </a>",
"      5 to 25 mg every six hours during the time of potential AWS.",
"     </li>",
"     <li>",
"      Consider obtaining a preoperative substance abuse consultation for complex patients and those with previous histories of AWS; early consultation with a substance abuse professional is preferable to delaying consultation until a patient is undergoing perioperative AWS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Operative recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific guidelines are available with regard to operative management of patients with AUDs, but based upon available research, anesthesiologists and surgeons should be aware of the presence of AUDs in order to anticipate variable responses and dosage requirements of anesthetics and analgesics.",
"   </p>",
"   <p>",
"    In cases of emergent surgery, AWS prophylaxis with benzodiazepines should be initiated for at-risk patients within a day after the last alcohol consumption. Suggested prophylactic regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    2.5 to 10 mg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 2 mg, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    5 to 25 mg every six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Postoperative recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be carefully monitored and frequently assessed to detect cardiopulmonary and infectious complications. Withdrawal should be assessed using standard assessment forms (eg, CIWA-Ar) (",
"      <a class=\"graphic graphic_table graphicRef64835 \" href=\"UTD.htm?20/61/21470\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with AUD can be expected to require prolonged intubations and ICU stays.",
"     </li>",
"     <li>",
"      Use of benzodiazepines according to established protocols have proven to be the most effective means to treat symptoms of AWS and limit its complications.",
"     </li>",
"     <li>",
"      Intravenous and oral alcohol are not recommended for use in patients with AUD.",
"     </li>",
"     <li>",
"      During detoxification after surgery, patients with AUD should be considered for referral to alcohol rehabilitation services and appropriate after care (eg, Alcoholics Anonymous). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"       \"Psychosocial treatment of alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/1\">",
"      Kip MJ, Neumann T, Jugel C, et al. New strategies to detect alcohol use disorders in the preoperative assessment clinic of a German university hospital. Anesthesiology 2008; 109:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/2\">",
"      O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998; 338:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/3\">",
"      Craft PP, Foil MB, Cunningham PR, et al. Intravenous ethanol for alcohol detoxification in trauma patients. South Med J 1994; 87:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/4\">",
"      Moore RD, Bone LR, Geller G, et al. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA 1989; 261:403.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. In: Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/6\">",
"      Berman S, Barilich JE, Rosenheck R, Koerber G. The VA's first comprehensive homeless center: a catalyst for public and private partnerships. Hosp Community Psychiatry 1993; 44:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/7\">",
"      Bradley KA, Bush KR, Davis TM, et al. Binge drinking among female Veterans Affairs patients: prevalence and associated risks. Psychol Addict Behav 2001; 15:297.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute on Alcohol Abuse and Alcoholism. In: The physicians' guide to helping patients with alcohol problems, National Institutes of Health, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/9\">",
"      Wechsler H, Dowdall GW, Davenport A, Rimm EB. A gender-specific measure of binge drinking among college students. Am J Public Health 1995; 85:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/10\">",
"      Wechsler H, Lee JE, Kuo M, Lee H. College binge drinking in the 1990s: a continuing problem. Results of the Harvard School of Public Health 1999 College Alcohol Study. J Am Coll Health 2000; 48:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/11\">",
"      A cross-national trial of brief interventions with heavy drinkers. WHO Brief Intervention Study Group. Am J Public Health 1996; 86:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/12\">",
"      Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res 1997; 21:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/13\">",
"      Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995; 56:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/14\">",
"      Reid MC, Fiellin DA, O'Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 1999; 159:1681.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician's guide (NIH Publication No. 05-3769). U.S. Department of Health &amp; Human Services, Rockville, MD 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/16\">",
"      Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993; 88:791.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. In: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines, World Health Organization, Geneva, Switzerland 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/18\">",
"      Stockwell T, Bolt L, Milner I, et al. Home detoxification from alcohol: its safety and efficacy in comparison with inpatient care. Alcohol Alcohol 1991; 26:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/19\">",
"      Whitfield CL, Thompson G, Lamb A, et al. Detoxification of 1,024 alcoholic patients without psychoactive drugs. JAMA 1978; 239:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/20\">",
"      Turner RC, Lichstein PR, Peden JG Jr, et al. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/21\">",
"      Spies C, T&oslash;nnesen H, Andreasson S, et al. Perioperative morbidity and mortality in chronic alcoholic patients. Alcohol Clin Exp Res 2001; 25:164S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/22\">",
"      Foy A, Kay J. The incidence of alcohol-related problems and the risk of alcohol withdrawal in a general hospital population. Drug Alcohol Rev 1995; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/23\">",
"      Foy A, Kay J, Taylor A. The course of alcohol withdrawal in a general hospital. QJM 1997; 90:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/24\">",
"      T&oslash;nnesen H, Petersen KR, H&oslash;jgaard L, et al. Postoperative morbidity among symptom-free alcohol misusers. Lancet 1992; 340:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/25\">",
"      Tonnesen H, Kehlet H. Preoperative alcoholism and postoperative morbidity. Br J Surg 1999; 86:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/26\">",
"      Nath B, Li Y, Carroll JE, et al. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg 2010; 14:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/27\">",
"      Bradley KA. Screening and diagnosis of alcoholism in the primary care setting. West J Med 1992; 156:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/28\">",
"      Fleming MF. Screening and brief intervention for alcohol disorders. J Fam Pract 1993; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/29\">",
"      Isaacson JH, Schorling JB. Screening for alcohol problems in primary care. Med Clin North Am 1999; 83:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/30\">",
"      Lewis CM, Eurman GH, Mineo RM. A simple preoperative method of screening for alcoholism. Ann Plast Surg 1992; 28:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/31\">",
"      Maisto SA, Connors GJ, Allen JP. Contrasting self-report screens for alcohol problems: a review. Alcohol Clin Exp Res 1995; 19:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/32\">",
"      Saitz R. Screening tests for alcohol use disorders. Ann Intern Med 1999; 130:779; author reply 779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/33\">",
"      Willenbring ML, Christensen KJ, Spring WD Jr, Rasmussen R. Alcoholism screening in the elderly. J Am Geriatr Soc 1987; 35:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/34\">",
"      Martin MJ, Heymann C, Neumann T, et al. Preoperative evaluation of chronic alcoholics assessed for surgery of the upper digestive tract. Alcohol Clin Exp Res 2002; 26:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/35\">",
"      Oppedal K, M&oslash;ller AM, Pedersen B, T&oslash;nnesen H. Preoperative alcohol cessation prior to elective surgery. Cochrane Database Syst Rev 2012; 7:CD008343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/36\">",
"      Tonnesen H, Rosenberg J, Nielsen HJ, et al. Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. BMJ 1999; 318:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/37\">",
"      Shourie S, Conigrave KM, Proude EM, et al. The effectiveness of a tailored intervention for excessive alcohol consumption prior to elective surgery. Alcohol Alcohol 2006; 41:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/38\">",
"      Spies CD, Nordmann A, Brummer G, et al. Intensive care unit stay is prolonged in chronic alcoholic men following tumor resection of the upper digestive tract. Acta Anaesthesiol Scand 1996; 40:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/39\">",
"      Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/40\">",
"      Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/41\">",
"      Lieber CS. Medical disorders of alcoholism. N Engl J Med 1995; 333:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/42\">",
"      Fassoulaki A, Farinotti R, Servin F, Desmonts JM. Chronic alcoholism increases the induction dose of propofol in humans. Anesth Analg 1993; 77:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/43\">",
"      Tammisto T, Tigerstedt I. The need for fentanyl supplementation of N2O-O2 relaxant anaesthesia in chronic alcoholics. Acta Anaesthesiol Scand 1977; 21:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/44\">",
"      St Haxholdt O, Krintel JJ, Johansson G. Pre-operative alcohol infusion. The need for analgesic supplementation in chronic alcoholics. Anaesthesia 1984; 39:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/45\">",
"      Kehlet H. The surgical stress response: should it be prevented? Can J Surg 1991; 34:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/46\">",
"      Newsome HH Jr. Ethanol modulation of plasma norepinephrine response to trauma and hemorrhage. J Trauma 1988; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/47\">",
"      Linnoila M, Mefford I, Nutt D, Adinoff B. NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med 1987; 107:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/48\">",
"      Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am 2001; 85:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/49\">",
"      T&oslash;nnesen H, Sch&uuml;tten BT, J&oslash;rgensen BB. Influence of alcohol on morbidity after colonic surgery. Dis Colon Rectum 1987; 30:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/50\">",
"      Sonne NM, T&oslash;nnesen H. The influence of alcoholism on outcome after evacuation of subdural haematoma. Br J Neurosurg 1992; 6:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/51\">",
"      T&oslash;nnesen H, Pedersen A, Jensen MR, et al. Ankle fractures and alcoholism. The influence of alcoholism on morbidity after malleolar fractures. J Bone Joint Surg Br 1991; 73:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/52\">",
"      T&oslash;nnesen H, Sch&uuml;tten BT, Tollund L, et al. Influence of alcoholism on morbidity after transurethral prostatectomy. Scand J Urol Nephrol 1988; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/53\">",
"      Felding C, Jensen LM, T&oslash;nnesen H. Influence of alcohol intake on postoperative morbidity after hysterectomy. Am J Obstet Gynecol 1992; 166:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/54\">",
"      Passeri LA, Ellis E 3rd, Sinn DP. Relationship of substance abuse to complications with mandibular fractures. J Oral Maxillofac Surg 1993; 51:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/55\">",
"      Okada S, Ishii H, Nose H, et al. Influence of alcohol abuse on recurrence after curative resection of hepatocellular carcinoma. Hepatogastroenterology 1995; 42:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/56\">",
"      Neuenschwander AU, Pedersen JH, Krasnik M, T&oslash;nnesen H. Impaired postoperative outcome in chronic alcohol abusers after curative resection for lung cancer. Eur J Cardiothorac Surg 2002; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/57\">",
"      Maxson PM, Schultz KL, Berge KH, et al. Probable alcohol abuse or dependence: a risk factor for intensive-care readmission in patients undergoing elective vascular and thoracic surgical procedures. Mayo Perioperative Outcomes Group. Mayo Clin Proc 1999; 74:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/58\">",
"      Rantala A, Lehtonen OP, Niinikoski J. Alcohol abuse: a risk factor for surgical wound infections? Am J Infect Control 1997; 25:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/59\">",
"      Jorgensen, LN, Tonnesen, H, Pedersen, S, et al. Reduced amounts of total protein in artificial wounds of alcohol abusers [abstract]. Br J Surg 1998; 85 Supp 2:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/60\">",
"      Morris PR, Mosby EL, Ferguson BL. Alcohol withdrawal syndrome: current management strategies for the surgery patient. J Oral Maxillofac Surg 1997; 55:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/61\">",
"      Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/62\">",
"      Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994; 272:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/63\">",
"      Spies CD, Dubisz N, Neumann T, et al. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med 1996; 24:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/64\">",
"      Blondell RD, Dodds HN, Blondell MN, et al. Ethanol in formularies of US teaching hospitals. JAMA 2003; 289:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/65\">",
"      Eggers V, Tio J, Neumann T, et al. Blood alcohol concentration for monitoring ethanol treatment to prevent alcohol withdrawal in the intensive care unit. Intensive Care Med 2002; 28:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/66\">",
"      Spies CD, Dubisz N, Funk W, et al. Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection. Br J Anaesth 1995; 75:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/67\">",
"      Gower WE, Kersten H. Prevention of alcohol withdrawal symptoms in surgical patients. Surg Gynecol Obstet 1980; 151:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/68\">",
"      Rose HD, Golbert TM, Sanz CJ, Leitschuh TH. Fever during acute alcohol withdrawal. Am J Med Sci 1970; 260:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/69\">",
"      Haxholdt OS, Johansson G. The alcoholic patient and surgical stress. Anaesthesia 1982; 37:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15577/abstract/70\">",
"      Hansbrough JF, Zapata-Sirvent RL, Carroll WJ, et al. Administration of intravenous alcohol for prevention of withdrawal in alcoholic burn patients. Am J Surg 1984; 148:266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7805 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15577=[""].join("\n");
var outline_f15_13_15577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALCOHOL USE DISORDERS SEEN IN SURGICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      At-risk drinking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alcohol withdrawal syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4648878\">",
"      Impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREOPERATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREOPERATIVE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abstinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preoperative detoxification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alcohol withdrawal syndrome prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Referral to addiction specialist prior to surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Response to anesthesia and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other intraoperative considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTOPERATIVE COMPLICATIONS AND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alcohol withdrawal syndrome treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Preoperative recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Operative recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Postoperative recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/5/12379\" title=\"table 1\">",
"      Timing of withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/32/22029\" title=\"table 2\">",
"      Diff dx postop delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/61/21470\" title=\"table 3\">",
"      CIWA-Ar withdrawal scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_13_15578="Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma";
var content_f15_13_15578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/13/15578/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/13/15578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL), formerly called Hodgkin's disease, arises from germinal center or post-germinal center B cells. HL has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells (",
"    <a class=\"graphic graphic_table graphicRef76591 \" href=\"UTD.htm?42/35/43579\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classical HL &mdash; The tumor cells in this group are also derived from germinal center B cells, but typically fail to express many of the genes and gene products that define normal germinal center B cells. Based on differences in the appearance of the tumor cells and the composition of the reactive background, classical HL is further divided into the following subtypes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nodular sclerosis classical HL (NSHL)",
"     </li>",
"     <li>",
"      Mixed cellularity classical HL (MCHL)",
"     </li>",
"     <li>",
"      Lymphocyte rich classical HL (LRHL)",
"     </li>",
"     <li>",
"      Lymphocyte depleted classical HL (LDHL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular lymphocyte predominant HL &mdash; The tumor cells in this subtype retain the immunophenotypic features of germinal center B cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The immunophenotype and genetic features of classical HL will be reviewed here. The features and diagnosis of NLPHL is presented separately, as are those of the non-Hodgkin lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The origin of the Reed-Sternberg cell and our current understanding of the pathogenesis of HL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"     \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence and age distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL) accounts for approximately 10 percent of all lymphomas and approximately 0.6 percent of all cancers diagnosed in the developed world annually [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/1\">",
"     1",
"    </a>",
"    ]. This amounts to approximately 9290 new cases and about 1180 deaths due to HL in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence in Europe is approximately 2.4 cases per 100,000 persons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HL has a bimodal age distribution curve. The pattern of age-specific incidence differs by geographic location and appears to parallel the level of industrial development:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the US and other economically advantaged countries, there is one peak in young adults (approximately age 20 years) and one in older age (approximately age 65 years); the majority of patients are young adults (",
"      <a class=\"graphic graphic_figure graphicRef62585 \" href=\"UTD.htm?29/42/30383\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/5\">",
"       5",
"      </a>",
"      ]. There is a slight male predominance, especially in children and in middle and older adulthood. The incidence pattern may vary at least partially by race. In one population-based study, the peak incidence was in young adulthood among Whites, Blacks, and",
"      <span class=\"nowrap\">",
"       Asians/Pacific",
"      </span>",
"      islanders and in older age among Hispanics [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In economically disadvantaged areas, there is an initial peak in childhood for boys, relatively low rates in young adults, and a late peak in older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An intermediate pattern with both a childhood and a second decade peak has been described in early industrialized or transitional economies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variance in histologic subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant histologic subtype also differs by geographic location and economic advancement. In developed countries such as the US, nodular sclerosis HL (NSHL) is the predominant histologic subtype and accounts for most of the peak in young adults. In economically disadvantaged areas, mixed cellularity HL (MCHL) is more frequent in children and older adults. Early industrialized or transitional economies tend to have an equal frequency of MCHL and NSHL subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US and Europe, the approximate percentage of classic HL cases from each subgroup are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nodular sclerosis classical HL (70 percent)",
"     </li>",
"     <li>",
"      Mixed cellularity classical HL (20 to 25 percent)",
"     </li>",
"     <li>",
"      Lymphocyte rich classical HL (5 percent)",
"     </li>",
"     <li>",
"      Lymphocyte depleted classical HL (less than 1 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Socioeconomic status and the environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In economically advantaged countries, the risk of developing HL as a young adult is consistently associated with factors indicative of a high standard of living in early childhood, including single family housing and small family size. These associations appear to be specific for the nodular sclerosis subtype of HL and for disease occurring from early childhood through middle adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In comparison, the risk pattern for the mixed cellularity HL (MCHL) subtype is inversely related to socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/13\">",
"     13",
"    </a>",
"    ]. Among lower socioeconomic groups in economically advantaged populations, cases of HL are predominantly of MCHL and lymphocyte depleted HL (LDHL) subtypes, and are more frequently Epstein Barr virus (EBV) positive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data associating socioeconomic status with the risk of HL are generally taken to implicate delayed exposure to a common etiologic environmental or infectious agent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. The specific exposure that is important is not clear. The following are observations regarding potential exposures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There appears to be an increased risk of HL in patients with a history of infectious mononucleosis caused by Epstein Barr virus (EBV) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link&amp;anchor=H4#H4\">",
"       \"The role of Epstein-Barr virus in Hodgkin lymphoma\", section on 'Association with infectious mononucleosis and EBV'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other childhood infectious illnesses including chickenpox, measles, mumps, rubella, and pertussis are negatively associated with the risk of HL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition, there is no evidence that cytomegalovirus, human herpesvirus 6, 7, or 8, polyoma JC virus, adenovirus types 5 and 12, human T cell lymphotropic virus 1 or 2, or human retrovirus 5 are present in the tumor cells of HL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/15,24\">",
"       15,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A protective effect of breastfeeding has been shown in multiple studies, but it is not known if this is due to transmitted maternal antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from population-based case-control studies have raised the possibility that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use may protect against the development of HL while smoking may increase the risk [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/27-30\">",
"       27-30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HL is increased in a number of settings associated with immunodeficiency, including solid organ or hematopoietic cell transplantation, therapy with immunosuppressive drugs (eg, in patients with autoimmune disease), and HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. As an example, among patients infected with HIV, the relative risk of HL is increased in various studies from fivefold to 25-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, the increase in risk for HL in immunosuppressed populations is less striking than that for non-Hodgkin lymphomas (NHLs) and the timing of HL and NHL development also differs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. As an example, the peak incidence of HL is four or more years after solid organ or hematopoietic cell transplantation, in contrast to NHL, which most commonly occurs in the first year after transplantation. In addition, NHL is primarily associated with marked immunosuppression, while patients with near-normal CD4 counts may develop HL. Almost all HL cases occurring in the setting of HIV infection are EBV-positive and many belong to the otherwise rare lymphocyte-depletion subtype. Given that T cell immunity is essential to hold EBV-transformed cells in check, these associations suggest that HIV-induced immunosuppression is at least partly responsible for the increased incidence of HL in HIV infected individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of autoimmune disorders are at increased risk for the development of HL and can pose challenging management issues due to comorbidities and late treatment related toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/41\">",
"     41",
"    </a>",
"    ]. The association between personal and familial histories of autoimmune diseases and risk for HL was evaluated in a large population-based case-control study using linked registry data from Sweden and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/42\">",
"     42",
"    </a>",
"    ]. The following significant risks for the development of HL were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A personal history of rheumatoid arthritis (OR 2.7; 95% CI 1.9-4.0), systemic lupus erythematosus (OR 5.8; 95% CI 2.2-15), or sarcoidosis (OR 14; 95% CI 5.4-37).",
"     </li>",
"     <li>",
"      A family history of sarcoidosis (OR 1.8; 95% CI 1.0-3.1) or ulcerative colitis (OR 1.6; 95% CI 1.0-2.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk in family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing HL is higher among relatives of patients with HL, possibly due to genetic susceptibility and the common environmental exposure in family members. Overall, the increased risk of HL in close relatives of patients with HL is about three- to fivefold the expected rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. There appears to be increased risk (sevenfold) among siblings of younger, but not older adults with HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/46\">",
"     46",
"    </a>",
"    ], and the risk in identical twins appears to be increased about 100-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/47\">",
"     47",
"    </a>",
"    ]. There is a consistent association between certain HLA haplotypes and the risk of HL, especially HLA-A1, and to a lesser extent, HLA-B5, HLA-B8, and HLA-B18 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/48-54\">",
"     48-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with classical HL present with painless localized peripheral lymphadenopathy, typically involving the cervical region. Details on the clinical presentation of HL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical HL is a heterogeneous group of tumors characterized by the presence of a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. The morphology of the neoplastic cells and the composition of the inflammatory background differ depending upon the subtype of HL. However, the classical HL subtypes share a common immunophenotype, which differs from that of other lymphoma subtypes, including nodular lymphocyte predominant HL (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical HL is defined by the presence of diagnostic Reed-Sternberg (RS) cells in an inflammatory background containing a variable number of small lymphocytes, eosinophils, neutrophils, macrophages (also referred to as histiocytes), plasma cells, fibroblasts, and collagen fibers (",
"    <a class=\"graphic graphic_picture graphicRef69090 \" href=\"UTD.htm?30/57/31632\">",
"     picture 1",
"    </a>",
"    ). Of note, the presence of various types of reactive cells, particularly the numbers of infiltrating macrophages and eosinophils, may have prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic RS cells are large cells with slightly basophilic cytoplasm that have bilobed, double, or multiple nuclei and prominent, eosinophilic, inclusion-like nucleoli in at least two nuclei or nuclear lobes (",
"    <a class=\"graphic graphic_picture graphicRef69090 \" href=\"UTD.htm?30/57/31632\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79314 \" href=\"UTD.htm?8/27/8624\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, there are variants of neoplastic cells that may be seen, but may not be diagnostic (",
"    <a class=\"graphic graphic_figure graphicRef67667 \" href=\"UTD.htm?22/20/22857\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"Hodgkin cell\" may be used for mononuclear variants.",
"     </li>",
"     <li>",
"      \"Mummified cells\" are neoplastic cells that contain condensed cytoplasm and pyknotic reddish nuclei with smudgy chromatin (",
"      <a class=\"graphic graphic_picture graphicRef66711 \" href=\"UTD.htm?37/53/38737\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      \"Lacunar cells\" have multilobated nuclei, small nucleoli, and abundant, pale cytoplasm that often \"retracts\" during tissue fixation and sectioning, leaving the nucleus in what appears to be an empty space (lacune) (",
"      <a class=\"graphic graphic_picture graphicRef66711 \" href=\"UTD.htm?37/53/38737\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The \"lymphocytic and histiocytic\" (L&amp;H) variants, sometimes referred to as \"popcorn cells\" have vesicular, polylobulated nuclei and distinct, small, usually peripheral nucleoli, without perinucleolar halos (",
"      <a class=\"graphic graphic_picture graphicRef82911 \" href=\"UTD.htm?0/39/633\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The composition of the background infiltrate and the morphology of the neoplastic cells vary by histologic subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nodular sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular sclerosis HL (NSHL) is characterized by an at least a partially nodular growth pattern, with fibrous bands separating the nodules (",
"    <a class=\"graphic graphic_picture graphicRef54520 \" href=\"UTD.htm?12/36/12867\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76378 \" href=\"UTD.htm?17/1/17439\">",
"     picture 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59583 \" href=\"UTD.htm?2/56/2948\">",
"     picture 7",
"    </a>",
"    ). Areas of necrosis may be present, and diagnostic Reed Sternberg (RS) cells may be rare. Typically, the majority of the neoplastic cells are lacunar cells, which may form aggregates within the centers of nodules. The inflammatory background usually contains eosinophils, histiocytes, and neutrophils.",
"   </p>",
"   <p>",
"    Some histologic variants of NSHL have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some cases, the fibrous bands may be poorly developed and inconspicuous, making the distinction from other forms of classical HL difficult. This appearance has been referred to as the \"cellular phase\" of NSHL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Syncytial NSHL refers to tumors in which lacunar cells are found in large prominent aggregates or even sheets, which may lead to a focal loss of the nodular sclerotic pattern (",
"      <a class=\"graphic graphic_picture graphicRef82231 \" href=\"UTD.htm?40/32/41474\">",
"       picture 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/58\">",
"       58",
"      </a>",
"      ]. This variant appears to have a similar prognosis to typical NS [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mixed cellularity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed cellularity HL (MCHL) is a heterogeneous category of classic HL with a diffuse or vaguely nodular growth pattern without band-forming sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef72292 \" href=\"UTD.htm?13/47/14067\">",
"     picture 9",
"    </a>",
"    ). Fine interstitial fibrosis may be present, and classical diagnostic Reed Sternberg cells are easily identified. The background infiltrate is variable, but typically consists of eosinophils, neutrophils, histiocytes, and plasma cells, as shown in the left panel of the figure (",
"    <a class=\"graphic graphic_picture graphicRef62690 \" href=\"UTD.htm?26/11/26808\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lymphocyte rich",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocyte rich HL (LRHL) most commonly has a nodular growth pattern, but may be diffuse. Diagnostic Reed Sternberg (RS) cells are present, but there may also be mononuclear Hodgkin cells and sometimes cells resembling lymphocytic and histiocytic (L&amp;H) cells. The background infiltrate consists predominantly of lymphocytes, with rare or no eosinophils or neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef82910 \" href=\"UTD.htm?25/63/26618\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some cases of LRHL have a nodular pattern, containing remnants of regressed germinal centers, with both classic and variant RS cells in the mantle zones and interfollicular regions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/59\">",
"     59",
"    </a>",
"    ]. This entity has been termed \"follicular\" HL, or nodular lymphocyte rich classical HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lymphocyte depleted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocyte depleted HL (LDHL) has a diffuse growth pattern and often appears hypocellular, due to the presence of fibrosis, necrosis, and a paucity of inflammatory cells (",
"    <a class=\"graphic graphic_picture graphicRef53036 \" href=\"UTD.htm?15/30/15843\">",
"     picture 12",
"    </a>",
"    ); large numbers of classical Reed Sternberg (RS) cells and bizarre variants are present, as in the right panel of the figure (",
"    <a class=\"graphic graphic_picture graphicRef62690 \" href=\"UTD.htm?26/11/26808\">",
"     picture 10",
"    </a>",
"    ). Confluent sheets of RS cells may be present; the terms \"reticular\" variant or \"Hodgkin sarcoma\" have been used to describe such tumors (",
"    <a class=\"graphic graphic_picture graphicRef52406 \" href=\"UTD.htm?43/9/44176\">",
"     picture 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/56,61\">",
"     56,61",
"    </a>",
"    ]. This variant may be difficult to distinguish from anaplastic large cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunophenotyping of the neoplastic cells is very helpful in distinguishing classic HL from nodular lymphocyte predominant HL (NLPHL) and other lymphoma subtypes (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ). Despite compelling molecular evidence that Reed Sternberg (RS) cells are derived from germinal center or post-germinal center B cells, these cells typically fail to express a number of transcription factors that are found in normal germinal center B cells and other malignancies derived from these cells, such as follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In classical HL, the RS cells typically express CD15 (85 percent of cases) and CD30 (virtually 100 percent of cases), and usually lack global expression of pan-B (CD19, CD20, CD79a) and pan-T (CD3, CD7) antigens (",
"    <a class=\"graphic graphic_picture graphicRef73875 graphicRef54023 \" href=\"UTD.htm?21/7/21622\">",
"     picture 14A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/65\">",
"     65",
"    </a>",
"    ]. However, approximately 95 percent of cases are weakly positive for",
"    <span class=\"nowrap\">",
"     PAX-5/BSAP,",
"    </span>",
"    a transcription factor that is a master regulator of B cell development. In addition, many cases of classical HL have B cell antigen expression (CD20 more often than CD79a) on a proportion of the RS cells; B cell antigen expression is typically variable in intensity and not present in all cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Among classical forms of HL, CD20 expression is most frequently seen in the lymphocyte-rich HL subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/59,60,65,68\">",
"     59,60,65,68",
"    </a>",
"    ]. Expression of a single T cell antigen, such as CD4, may occasionally be seen on RS cells, but classical HL expressing multiple T cell antigens is rare; such tumors usually prove to be T cell lymphomas.",
"   </p>",
"   <p>",
"    In addition to CD15 and CD30, RS cells express CD25, HLA-DR, ICAM-1, CD95",
"    <span class=\"nowrap\">",
"     (apo-1/fas),",
"    </span>",
"    TRAF1 and both CD40 and CD86; the latter are molecules associated with B cell activation and T cell interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/66,67,69-72\">",
"     66,67,69-72",
"    </a>",
"    ]. T cells surrounding the RS cells express both CD40 ligand and CD28, the ligand for CD86 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/70,72\">",
"     70,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to NLPHL, the RS cells of classical HL often lack the nuclear BCL-6 protein associated with follicle center B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], and may express CD138, a plasma cell associated antigen. In Epstein Barr virus (EBV) positive cases, the tumor cells express EBV latent membrane protein (LMP)-1 but not Epstein-Barr nuclear antigen (EBNA)-2. Low-level expression of",
"    <span class=\"nowrap\">",
"     PAX-5/BSAP,",
"    </span>",
"    seen in most cases, is helpful in distinguishing classical HL from unusual T cell lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The loss of most B cell markers and the aberrant expression of markers of other lineages, such as T cell markers, indicates that the gene expression programs of RS cells are extremely deranged, a characteristic that explains why the origin of these cells remained mysterious for so long. Although the proximal cause of this alteration in gene expression is not yet understood, it is apparent that the expression and activity of many B cell specific \"master\" transcription factors is altered in classical RS cells.",
"   </p>",
"   <p>",
"    For example, the B cell-specific transcription factors Pu.1, Oct-2, and BOB1, which drive Ig expression, are usually decreased or undetectable, whereas certain factors that are expressed in T cells, such as Notch1, are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/64\">",
"     64",
"    </a>",
"    ]. Assessment of Oct-2 and BOB1 can be useful in distinction between classical HL and NLPHL or diffuse large B cell lymphoma (DLBCL) in difficult cases (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Epigenetic promoter silencing also contributes to the loss of expression of Ig and many other B cell-specific genes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Finally, although",
"    <span class=\"nowrap\">",
"     PAX-5/BSAP",
"    </span>",
"    is expressed in classical RS cells, its ability to activate target gene expression is abrogated, possibly because of its co-dependence on other transcription factors that are lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ig and TCR gene rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to detect immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements differs depending upon the technique used. In studies using the Southern blot technique or whole section polymerase chain reaction (PCR) to analyze total nodal DNA isolated from cases of classical HL, rearrangements of the immunoglobulin (Ig) and TCR genes were usually not detected. With more sensitive PCR techniques using single Reed Sternberg cells micromanipulated from frozen tissue sections, several groups documented the presence of clonal, somatically mutated VDJ rearrangements in most cases of classical HL, a molecular finding that indicates an origin from germinal center or post-germinal center B cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=see_link\">",
"     \"The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare cases of HL with T cell antigen expression, analysis of Ig and TCR genes has shown that the majority of these cases also have clonal Ig gene rearrangements; only about one-third of T cell antigen positive cases actually show TCR gene rearrangements and are truly of T cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cytogenetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal cytogenetic abnormalities are found in the majority of the cases of classical HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]; however, the abnormalities differ from case to case, and there is often intraclonal variability, indicating chromosome instability. Using fluorescence in-situ hybridization (FISH) with or without fluorescence immunophenotyping, two groups have demonstrated clonal abnormalities in chromosome number in all cases of HL tested [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many cases show 14q abnormalities that are typical for B cell lymphomas, however, t(14;18) occurs rarely, if at all. BCL-2 rearrangements have been detected using PCR techniques, but these rearrangements do not appear to be present within the RS cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/81\">",
"     81",
"    </a>",
"    ]. This is in line with other studies showing that the t(14;18) can be detected at low frequency in normal reactive germinal center B cells (approximately one cell in 1000).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV) involvement varies considerably among the subtypes of classical HL. EBV infection can be detected by immunohistochemistry for latent membrane protein-1 or by in situ hybridization for EBV small nuclear RNA transcripts (EBERs) (",
"    <a class=\"graphic graphic_picture graphicRef56344 \" href=\"UTD.htm?40/19/41270\">",
"     picture 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61104 \" href=\"UTD.htm?33/44/34497\">",
"     picture 16",
"    </a>",
"    ). Detection of EBV can be helpful in the differential diagnoses of classical HL and other lymphomas (eg, anaplastic large cell lymphoma), which are uniformly EBV negative.",
"   </p>",
"   <p>",
"    When present in RS cells, EBV is always carried as a latent episome. Genomic analyses have revealed that the configuration of the episomes in EBV positive tumors is identical (monoclonal) in each RS cell, indicating that viral infection precedes cellular transformation.",
"   </p>",
"   <p>",
"    EBV is found infrequently in nodular sclerosis HL, whereas it is detected in about 40 percent of lymphocyte rich HL, 70 percent of mixed cellularity HL, and close to 100 percent of lymphocyte depleted HL (LDHL). LDHL, a rare subtype, is also strongly associated with immunodeficiency states, such as HIV infection and AIDS, which may contribute to the high incidence of EBV infection in this subtype. Immunosuppression-associated HL is almost universally Epstein Barr virus (EBV)-associated and usually of the lymphocyte depleted or mixed cellularity subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/32,34,77,85-90\">",
"     32,34,77,85-90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2494013\">",
"    <span class=\"h3\">",
"     Molecular genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with microdissected RS cells have illuminated some of the genetic changes in these unusual tumor cells. Inactivating mutations in TNFAIP3, a gene that encodes a negative regulator of NF-kappaB called A20, have been reported in the RS cells of up to 44 percent of classical HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/91\">",
"     91",
"    </a>",
"    ]. These are hypothesized to lead to upregulation of NF-kappaB. Less common acquired genetic lesions involving other components of the NF-kappaB signaling pathway, such as mutations in aberrations involving TRAF3 and MAP3K14, have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441316973\">",
"    <span class=\"h3\">",
"     Expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression profiling studies have been performed on primary RS cells, also obtained through microdissection of tissues involved by HL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/93\">",
"     93",
"    </a>",
"    ]. These studies confirmed that the RS cells of classical HL have an expression profile distinct from other forms of lymphoma, that EBV+ and EBV- cases have similar expression profiles, and that there appear to be at least two classes of classical HL that are defined by differences in the activity of the transcription factors NOTCH1, MYC, and IRF4. In addition, there was frequent silencing of two potential tumor suppressors, BIK (a pro-apoptotic factor) and INPP5D (a negative regulator of PI3K signaling), in RS cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to devise a grading scheme for nodular sclerosis HL (NSHL) that can predict patient outcome with therapy. However, since no treatment protocols have been devised that take into account either of these grading schemes, there is currently no clinical mandate to use them in practice. Two grading schemes have been evaluated in sufficient detail to merit brief mention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      British National Lymphoma Investigation (BNLI) group grading &mdash; The BNLI group developed a grading system for NSHL, based on the number and atypia of the RS cells and the composition of the cellular background [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/94-96\">",
"       94-96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In grade 1 NS, lacunar cells are scattered singly in the nodules.",
"     </li>",
"     <li>",
"      In grade 2 NS, clusters or sheets of lacunar cells are present in at least 25 percent of the nodules. Cases of NSHL with a diffuse fibrotic background are also considered grade 2. Cases of grade II NSHL (NS2) include the syncytial NS variants described above.",
"      <br/>",
"      <br/>",
"      Based upon this system, about 75 to 85 percent of cases in most series are NS1 and 15 to 25 percent are NS2. In the BNLI series, compared with NS1 tumors, NS2 tumors had an increased rate of relapse, shorter survival, and a worse response to initial therapy. However, other groups have failed to detect any influence of NS grade on outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/97-102\">",
"       97-102",
"      </a>",
"      ]; this is particularly true of trials that began after 1980. These results suggest that, when treated with current therapeutic regimens, grade 2 NS has the same prognosis as grade 1 NS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      German Hodgkin Study Group (GHSG) grading &mdash; The GHSG has observed that, among patients with NSHL, eosinophilia (defined as &gt;5 percent eosinophils or eosinophil clusters present) in lymphomatous tissues is associated with a worse prognosis than tumors lacking these features [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/103\">",
"       103",
"      </a>",
"      ]. The GHSG has proposed two risk groups of NSHL, defined by the number of eosinophils and the prominence of neoplastic cells (high risk and low risk), which they found predicted outcome more accurately than the BNLI grading scheme [",
"      <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13483153\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HL is made by the evaluation of involved tissue, usually a lymph node biopsy. Excisional biopsies are preferred and large core needle biopsies may be adequate in select cases, but fine needle aspiration alone does not provide enough tissue or information on the structural composition of the lymph node to provide an accurate diagnosis. Evaluation of the biopsy material should include both routine light microscopy and analysis of the immunophenotype with immunohistochemistry. Since Reed-Sternberg cells are rare, genetic testing is difficult and not routinely used clinically.",
"   </p>",
"   <p>",
"    While typical cases may be diagnosed based upon routine light microscopy findings, it has become standard practice to perform confirmatory immunophenotyping. Analysis of the immunophenotype of both the neoplastic cells and the background infiltrate has helped to better define HL and its subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/65\">",
"     65",
"    </a>",
"    ]. It also is often critical in making the distinction between HL and T cell rich large B cell lymphoma and anaplastic large-cell lymphoma, two morphologically similar aggressive non-Hodgkin lymphomas that are treated differently than HL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13483160\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical HL is defined by the presence of diagnostic Reed-Sternberg cells in an inflammatory background containing a variable number of small lymphocytes, eosinophils, neutrophils, histiocytes, plasma cells, fibroblasts, and collagen fibers. Morphologic features also determine the various subtypes of classic HL. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Morphology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Classical HL typically expresses CD15 and CD30, variably expresses CD20, and does not express CD3 or CD45 (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ). Failure to detect CD15 does not preclude a diagnosis of HL; however, absence of both CD15 and CD30 and expression of CD20 should prompt reexamination of the slides and consideration of either nodular lymphocyte predominant HL (NLPHL), lymphocyte rich HL, or an unusual variant of large B cell NHL (eg,",
"    <span class=\"nowrap\">",
"     histiocyte/T",
"    </span>",
"    cell rich diffuse large B cell lymphoma). Expression of T cell antigens is unusual, and should prompt both re-review of the slides and molecular genetic analysis of the T cell receptor gene in order to rule out a T cell NHL. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Immunophenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of classic HL includes nodular lymphocyte predominant HL and varieties of non-Hodgkin lymphoma that may have similar clinical presentations or morphology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nodular lymphocyte predominant HL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocyte rich HL (LRHL) and nodular lymphocyte predominant HL (NLPHL) can have a similar clinical presentation with a predominance of early stage disease, non-bulky disease and an absence of B symptoms. In addition, they may have similar morphologic features, including the presence of RS cells and variants in a background of small B cells. Some cases of LRHL may even contain cells resembling lymphocytic and histiocytic (L&amp;H) RS cells, which are usually prominent in cases of NLPHL (",
"    <a class=\"graphic graphic_picture graphicRef82911 \" href=\"UTD.htm?0/39/633\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The key distinguishing feature between LRHL and NLPHL is the immunophenotype of the malignant cells (",
"    <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"     table 2",
"    </a>",
"    ). Unlike NLPHL, LRHL malignant cells have the immunophenotypic profile of classic HL. In addition, about 40 percent of LRHLs are Epstein-Barr virus (EBV) positive, while NLPHL is EBV negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reticular variant of lymphocyte depleted HL (LDHL) may be difficult to distinguish from anaplastic large cell lymphoma (ALCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In the past, some patients were diagnosed as having a variant of ALCL resembling HL of nodular sclerosis type (NSHD), originally called ALCL Hodgkin-related, and then called ALCL Hodgkin-like (ALCL-HL) in the REAL classification. This subtype was defined as having architectural features of HL (nodularity and sclerosis) but cytologic features of ALCL (sheets of neoplastic cells and sinusoidal infiltration).",
"   </p>",
"   <p>",
"    The current consensus is that the majority of these cases can be resolved by a combination of morphologic and immunophenotypic features as either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma (CD15+, CD30+,",
"      <span class=\"nowrap\">",
"       PAX/BSAP+,",
"      </span>",
"      T cell antigen -, ALK-)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma (CD15-, CD30+,",
"      <span class=\"nowrap\">",
"       PAX5/BSAP-,",
"      </span>",
"      T cell antigen",
"      <span class=\"nowrap\">",
"       +/-,",
"      </span>",
"      <span class=\"nowrap\">",
"       ALK+/-).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, this separate category has been eliminated from the current WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?15/13/15578/abstract/10\">",
"     10",
"    </a>",
"    ]. Nonetheless, there are occasional cases in which the combination of morphology, immunophenotype, and even genetic studies may not resolve ALCL and HL with certainty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diffuse large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSHL and a distinctive subtype of diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBL), share many clinical and pathologic features. They are both more common in young women and present with a mediastinal mass. On biopsy, PMBL may have cells that resemble the neoplastic Reed Sternberg (RS) cells of HL. In addition, gene expression profiling has shown a similarity between the two entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunophenotype can help to distinguish PMBL from HL most cases. In classical HL, the neoplastic RS cells typically express CD15 and CD30, and lack pan-B and pan-T cell antigens. In contrast, PMBL cells typically express pan-B cell antigens, have weak expression of CD30, and only rarely express CD15.",
"   </p>",
"   <p>",
"    There are occasional cases that combine features of PMBL and HL. Such cases are labeled \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma.\"",
"   </p>",
"   <p>",
"    In addition, HL must be differentiated from T cell histiocyte rich large B cell lymphoma (THRLBCL). THRLBCL occurs most commonly in middle-aged males. As in HL, the tumor cells often comprise a minor fraction of the total cellularity. Distinction from HL is usually not difficult, as the malignant B cells in THRLBCL usually have an immunophenotype similar to typical DLBCL (eg, positive for pan-B cell markers and negative for CD15, CD30, and EBV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'T cell histiocyte rich large B cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hodgkin lymphoma (HL) is a B cell lymphoma with a bimodal age distribution that accounts for approximately 10 percent of all lymphomas in economically advanced countries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HL is divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nodular lymphocyte predominant HL (NLPHL)",
"     </li>",
"     <li>",
"      Classical HL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic HL is usually diagnosed based upon the evaluation of a lymph node biopsy. On light microscopy, the tumor contains a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. The neoplastic cells typically express CD15 and CD30, variably express CD20, and do not express CD3 or CD45 (",
"      <a class=\"graphic graphic_table graphicRef57079 \" href=\"UTD.htm?17/23/17788\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on the appearance of the tumor cells and the composition of the reactive background, classical HL is further divided into the following four subtypes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nodular sclerosis classical HL (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Nodular sclerosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Mixed cellularity classical HL (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Mixed cellularity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lymphocyte rich classical HL (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Lymphocyte rich'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lymphocyte depleted classical HL (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Lymphocyte depleted'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis includes NLPHL and various forms of non-Hodgkin lymphoma. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/1\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/3\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/4\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Kosary CL, Hankey BF, et al. (Eds). SEER cancer statistics review: 1973-1994, NIH publ no. 97-2789, National Cancer Institute, Bethesda 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/6\">",
"      Evens AM, Antill&oacute;n M, Aschebrook-Kilfoy B, Chiu BC. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Ann Oncol 2012; 23:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/7\">",
"      Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 1971; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/8\">",
"      Correa P, O'Conor GT. Geographic pathology of lymphoreticular tumors: summary of survey from the geographic pathology committee of the international union against cancer. J Natl Cancer Inst 1973; 50:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/9\">",
"      Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981; 304:135.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/11\">",
"      Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev 1992; 1:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/12\">",
"      Glaser SL. Regional variation in Hodgkin's disease incidence by histologic subtype in the US. Cancer 1987; 60:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/13\">",
"      McNally RJ, Alston RD, Cairns DP, et al. Geographical and ecological analyses of childhood acute leukaemias and lymphomas in north-west England. Br J Haematol 2003; 123:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/14\">",
"      Hu E, Hufford S, Lukes R, et al. Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncol 1988; 6:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/15\">",
"      Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin Hematol 1999; 36:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/16\">",
"      Flavell KJ, Biddulph JP, Powell JE, et al. South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. Br J Cancer 2001; 85:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/17\">",
"      Vianna NJ, Greenwald P, Brady J, et al. Hodgkin's disease: cases with features of a community outbreak. Ann Intern Med 1972; 77:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/18\">",
"      Vianna NJ, Polan AK. Epidemiologic evidence for transmission of Hodgkin's disease. N Engl J Med 1973; 289:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/19\">",
"      Grufferman S, Cole P, Levitan TR. Evidence against transmission of Hodgkin's disease in high schools. N Engl J Med 1979; 300:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/20\">",
"      Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989; 320:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/21\">",
"      Lehtinen T, Lumio J, Dillner J, et al. Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control 1993; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/22\">",
"      Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000; 82:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/23\">",
"      Hjalgrim H, Askling J, S&oslash;rensen P, et al. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 2000; 92:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/24\">",
"      Armstrong AA, Shield L, Gallagher A, Jarrett RF. Lack of involvement of known oncogenic DNA viruses in Epstein-Barr virus-negative Hodgkin's disease. Br J Cancer 1998; 77:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/25\">",
"      Grufferman S, Davis MK, Ambinder RF, et al. A protective effect of breast-feeding on risk of Hodgkin's disease in children. Paediatr Perinat Epidemiol 1998; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/26\">",
"      Davis MK, Savitz DA, Graubard BI. Infant feeding and childhood cancer. Lancet 1988; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/27\">",
"      Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004; 96:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/28\">",
"      Nieters A, Rohrmann S, Becker N, et al. Smoking and lymphoma risk in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008; 167:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/29\">",
"      Castillo JJ, Dalia S, Shum H. Meta-analysis of the association between cigarette smoking and incidence of Hodgkin's Lymphoma. J Clin Oncol 2011; 29:3900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/30\">",
"      Kroll ME, Murphy F, Pirie K, et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer 2012; 107:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/31\">",
"      Goedert JJ, Cot&eacute; TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/32\">",
"      Tinguely M, Vonlanthen R, M&uuml;ller E, et al. Hodgkin's disease-like lymphoproliferative disorders in patients with different underlying immunodeficiency states. Mod Pathol 1998; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/33\">",
"      Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/34\">",
"      Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996; 61:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/35\">",
"      Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/36\">",
"      Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/37\">",
"      Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/38\">",
"      Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/39\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/40\">",
"      Spina M, Berretta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/41\">",
"      Landgren O, Pfeiffer RM, Kristinsson SY, Bj&ouml;rkholm M. Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. J Clin Oncol 2010; 28:5081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/42\">",
"      Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/43\">",
"      Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/44\">",
"      Goldin LR, Bj&ouml;rkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/45\">",
"      Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004; 96:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/46\">",
"      Grufferman S, Cole P, Smith PG, Lukes RJ. Hodgkin's disease in siblings. N Engl J Med 1977; 296:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/47\">",
"      Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995; 332:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/48\">",
"      Oza AM, Tonks S, Lim J, et al. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. Cancer Res 1994; 54:5101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/49\">",
"      Harty LC, Lin AY, Goldstein AM, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 2002; 99:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/50\">",
"      Kamper PM, Kjeldsen E, Clausen N, et al. Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings. Br J Haematol 2005; 129:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/51\">",
"      Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005; 365:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/52\">",
"      Huang X, Kushekhar K, Nolte I, et al. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups. Blood 2011; 118:5211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/53\">",
"      Cozen W, Li D, Best T, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood 2012; 119:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/54\">",
"      Huang X, Kushekhar K, Nolte I, et al. HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One 2012; 7:e39986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/55\">",
"      Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012; 120:3280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/56\">",
"      Lukes R, Butler J, Hicks E. Natural history of Hodgkin's disease as related to its pathological picture. Cancer 1966; 19:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/57\">",
"      Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/58\">",
"      Strickler JG, Michie SA, Warnke RA, Dorfman RF. The \"syncytial variant\" of nodular sclerosing Hodgkin's disease. Am J Surg Pathol 1986; 10:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/59\">",
"      Sextro M, Diehl V, Franklin J, et al. Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma. Ann Oncol 1996; 7 Suppl 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/60\">",
"      Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG. Follicular Hodgkin's disease. Am J Surg Pathol 1995; 19:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/61\">",
"      Neiman RS, Rosen PJ, Lukes RJ. Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity. N Engl J Med 1973; 288:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/62\">",
"      Leoncini L, Del Vecchio MT, Kraft R, et al. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas--a continuous spectrum of malignant disorders. A quantitative morphometric and immunohistologic study. Am J Pathol 1990; 137:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/63\">",
"      Stein H, Herbst H, Anagnostopoulos I, et al. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma. Ann Oncol 1991; 2 Suppl 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/64\">",
"      Schmitz R, Stanelle J, Hansmann ML, K&uuml;ppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/65\">",
"      von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/66\">",
"      Zukerberg LR, Collins AB, Ferry JA, Harris NL. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 1991; 139:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/67\">",
"      Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol 1991; 139:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/68\">",
"      von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997; 150:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/69\">",
"      Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/70\">",
"      Munro JM, Freedman AS, Aster JC, et al. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/71\">",
"      Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007; 25:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/72\">",
"      Kanzler H, K&uuml;ppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/73\">",
"      Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996; 87:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/74\">",
"      Carbone A, Gloghini A, Gaidano G, et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 1998; 92:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/75\">",
"      Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/76\">",
"      Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003; 120:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/77\">",
"      Ushmorov A, Leith&auml;user F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/78\">",
"      Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004; 104:3326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/79\">",
"      Doerr JR, Malone CS, Fike FM, et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol 2005; 350:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/80\">",
"      M&uuml;schen M, Rajewsky K, Br&auml;uninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000; 191:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/81\">",
"      Poppema S, Kaleta J, Hepperle B. Chromosomal abnormalities in patients with Hodgkin's disease: evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells. J Natl Cancer Inst 1992; 84:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/82\">",
"      M'kacher R, Bennaceur-Griscelli A, Girinsky T, et al. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007; 68:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/83\">",
"      Weber-Matthiesen K, Deerberg J, Poetsch M, et al. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 1995; 86:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/84\">",
"      Inghirami G, Macri L, Rosati S, et al. The Reed-Sternberg cells of Hodgkin disease are clonal. Proc Natl Acad Sci U S A 1994; 91:9842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/85\">",
"      Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999; 93:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/86\">",
"      Levine AM. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/87\">",
"      Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol 1992; 167:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/88\">",
"      Pelstring RJ, Zellmer RB, Sulak LE, et al. Hodgkin's disease in association with human immunodeficiency virus infection. Pathologic and immunologic features. Cancer 1991; 67:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/89\">",
"      Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/90\">",
"      Herndier BG, Sanchez HC, Chang KL, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Am J Pathol 1993; 142:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/91\">",
"      Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/92\">",
"      Otto C, Giefing M, Massow A, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012; 157:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/93\">",
"      Tiacci E, D&ouml;ring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120:4609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/94\">",
"      Bennett MH, MacLennan KA, Easterling MJ, et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol 1983; 34:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/95\">",
"      MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989; 64:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/96\">",
"      Haybittle JL, Hayhoe FG, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; 1:967.",
"     </a>",
"    </li>",
"    <li>",
"     Michel G, Bouzourene H, Delacretaz F, et al. Histologic grade of nodular sclerosing Hodgkin's disease: Is it a prognostic factor? Third International Symposium on Hodgkin's lymphoma, Kolne, Germany 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/98\">",
"      van Spronsen DJ, Vrints LW, Hofstra G, et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol 1997; 96:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/99\">",
"      Ferry JA, Linggood RM, Convery KM, et al. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer 1993; 71:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/100\">",
"      Wijlhuizen TJ, Vrints LW, Jairam R, et al. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value? Cancer 1989; 63:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/101\">",
"      Hess JL, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994; 74:708.",
"     </a>",
"    </li>",
"    <li>",
"     Georgii A, Hasenclever D, Fischer R, et al. Histopathological grading of nodular sclerosing Hodgkin's reveals significant differences in survival and relapse rather under protocOl-therapy. Third International Symposuim on Hodgkin's lymphoma, September, Kolne, Germany 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/103\">",
"      von Wasielewski R, Seth S, Franklin J, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000; 95:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/13/15578/abstract/104\">",
"      von Wasielewski S, Franklin J, Fischer R, et al. Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages. Blood 2003; 101:4063.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4691 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15578=[""].join("\n");
var outline_f15_13_15578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence and age distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variance in histologic subtype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Socioeconomic status and the environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk in family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nodular sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mixed cellularity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lymphocyte rich",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lymphocyte depleted",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ig and TCR gene rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2494013\">",
"      - Molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441316973\">",
"      - Expression profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Grading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13483153\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13483160\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nodular lymphocyte predominant HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4691|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/42/30383\" title=\"figure 1\">",
"      Age distribution in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/20/22857\" title=\"figure 2\">",
"      HL neoplast cell variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4691|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/57/31632\" title=\"picture 1\">",
"      Diagnostic Reed-Sternberg cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/27/8624\" title=\"picture 2\">",
"      Two nuclei diagnostic Reed-Sternberg cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/53/38737\" title=\"picture 3\">",
"      Lacunar cells and mummified Reed-Sternberg cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/39/633\" title=\"picture 4\">",
"      Nodular lymphocyte-predominant HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/36/12867\" title=\"picture 5\">",
"      Nodular sclerosis HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/1/17439\" title=\"picture 6\">",
"      Lymph node Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/56/2948\" title=\"picture 7\">",
"      Nodular sclerosis Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/32/41474\" title=\"picture 8\">",
"      Syncytial form nodular sclerosis HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14067\" title=\"picture 9\">",
"      Mixed-cellularity Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/11/26808\" title=\"picture 10\">",
"      Mixed cell versus lymphocyte depletion HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/63/26618\" title=\"picture 11\">",
"      Lymphocyte-rich type HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/30/15843\" title=\"picture 12\">",
"      Lymphocyte depletion HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/9/44176\" title=\"picture 13\">",
"      Lymphocyte depletion diffuse fibrous type HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/48/29441\" title=\"picture 14A\">",
"      Immunostaining for CD30 in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/52/34624\" title=\"picture 14B\">",
"      Immunostaining for CD15 in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/19/41270\" title=\"picture 15\">",
"      EBV gene expression in Reed-Sternberg cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/44/34497\" title=\"picture 16\">",
"      Immunostaining for EBV LMP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/35/43579\" title=\"table 1\">",
"      Hodgkin classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/23/17788\" title=\"table 2\">",
"      Hodgkin immunophenotype",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/23/2426?source=related_link\">",
"      The Reed-Sternberg cell and the pathogenesis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=related_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_13_15579="Frequency malignant OGCNs";
var content_f15_13_15579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of histologic types among malignant ovarian germ cell neoplasms: United States Surveillance Epidemiology and End Results national cancer database (1262 tumors; 1973 to 2002)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysgerminomas",
"       </td>",
"       <td>",
"        32.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immature teratomas",
"       </td>",
"       <td>",
"        35.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mature teratomas with malignant degeneration",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endodermal sinus (yolk sac)",
"       </td>",
"       <td>",
"        14.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embryonal",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed germ cell tumors",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teratocarcinoma",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Smith HO. Obstet Gynecol 2006; 107:1075.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15579=[""].join("\n");
var outline_f15_13_15579=null;
var title_f15_13_15580="Distinction between arousal parasomnias and nocturnal seizures";
var content_f15_13_15580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinction between arousal parasomnias and nocturnal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arousal parasomnias",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nocturnal seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of onset",
"       </td>",
"       <td>",
"        Preschool age and childhood",
"       </td>",
"       <td>",
"        Infancy, preschool age, childhood, and adolescence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of similar events",
"       </td>",
"       <td>",
"        May be positive",
"       </td>",
"       <td>",
"        May or may not be positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time of occurrence",
"       </td>",
"       <td>",
"        First third of night sleep (usually)",
"       </td>",
"       <td>",
"        Randomly through the night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most common sleep stage at occurrence",
"       </td>",
"       <td>",
"        Slow wave sleep",
"       </td>",
"       <td>",
"        Stages I or II of NREM sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of event",
"       </td>",
"       <td>",
"        5-30 minutes",
"       </td>",
"       <td>",
"        0.5 to 5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple events on a single night",
"       </td>",
"       <td>",
"        Less likely",
"       </td>",
"       <td>",
"        More likely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polysomnogram (with EEG)",
"       </td>",
"       <td>",
"        Rhythmic theta or delta activity",
"       </td>",
"       <td>",
"        Normal, OR spikes or sharp waves over a focal or generalized distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usual daytime behavior",
"       </td>",
"       <td>",
"        Normal (unless complicated by sleep related breathing disturbance or restless legs/periodic limb movement disorder)",
"       </td>",
"       <td>",
"        May be irritable and sleepy; seizures may also occur during the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmacological therapy",
"       </td>",
"       <td>",
"        Benzodiazepine at bedtime",
"       </td>",
"       <td>",
"        Daytime and bedtime administration of oxcarbazepine, lamotrigine, levetiracetam, carbamazepine, or phenytoin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NREM: non rapid eye movement; EEG: electroencephalogram.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kotagal S. Parasomnias of childhood. Curr Opin Pediatr 2008; 20:659. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15580=[""].join("\n");
var outline_f15_13_15580=null;
var title_f15_13_15581="Low protein preserves GFR in DM";
var content_f15_13_15581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing effect of dietary protein restriction on progression of diabetic nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 208px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dietary protein restriction - to about 0.6 g/kg per day or 30 to 40 percent lower than the control group - in two trials (left and right panels) of patients with type 1 diabetes and diabetic nephropathy led to a 75 percent reduction in the rate of loss of glomerular filtration rate (GFR) at 18 to 36 months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Walker JD, Bending JJ, Dodds RA, et al, Lancet 1989; 2:1411.",
"     <br>",
"      Zeller K, Whittaker E, Sullivan L, et al. N Engl J Med 1991; 324:78.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15581=[""].join("\n");
var outline_f15_13_15581=null;
var title_f15_13_15582="Median BMI percentiles in patients with cystic fibrosis";
var content_f15_13_15582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Median BMI percentiles in patients with cystic fibrosis, 1990 through 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this figure, the \"goal\"&nbsp;is defined as a&nbsp;body mass index (BMI) greater than the 50th percentile for age and gender, using the growth reference from the Centers for Disease Control (CDC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry 2010 Annual Data Report, Bethesda, MD. Copyright &copy; 2011 Cystic Fibrosis Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15582=[""].join("\n");
var outline_f15_13_15582=null;
var title_f15_13_15583="Trunk rash secondary syphilis";
var content_f15_13_15583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trunk rash secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dylewski, J, Duong, M. The rash of secondary syphilis. CMAJ 2007; 176:33. Copyright &copy;2007 Canadian Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_13_15583=[""].join("\n");
var outline_f15_13_15583=null;
